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Abstract 
Municipal wastewater treatment plant effluent (MWWE) is a complex matrix that acts as 
a significant source of contaminants to aquatic receiving environments. Contaminants of 
emerging concern (CECs) are known to affect aquatic organisms downstream of MWWE 
discharges. Past studies in the Grand River watershed of southern Ontario on the small-bodied, 
benthic rainbow darter (Etheostoma caeruleum) have shown altered gene expression, sex steroid 
levels, gonad size and expression of intersex (testis-ova) associated with wastewater outfalls. The 
Region of Waterloo is upgrading the two major wastewater treatment plants (WWTP) within the 
Grand River watershed (Waterloo, Kitchener) where biological impacts in the receiving waters 
have been observed. Although extensive research is currently being performed in the Grand 
River to determine the biological impacts of WWTP upgrades on exposed fish and benthos, there 
was no comprehensive work being done on the chemistry of the effluent itself. The objectives of 
the current study were to determine how process changes and temporal variability altered the 
concentration of select CECs present in the effluent as well as the total estrogenicity of the 
discharged effluent. Archived and current effluent samples from 2009 through to 2015 were 
analyzed for select CECs with LC-MS/MS as well as total estrogenicity with the Yeast Estrogen 
Screen assay. Concentrations of selected pharmaceuticals, such as ibuprofen and naproxen, are 
greatly reduced with nitrifying treatment while other contaminants such as carbamazepine and 
diclofenac remain recalcitrant. The removal of key CECs varies dependent on their 
physiochemical properties, with readily biotransformed CECs the most effectively removed by 
the WWTP after a transition to nitrifying treatment.  
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Increased understanding of how major upgrades to treatment plant infrastructure alter the 
contaminant concentrations in wastewater effluent will greatly improve our ability to inform 
future watershed regulatory decision-making. These improvements have potential significance 
for the environment downstream of the WWTPs where endocrine disruption has been 
documented, including high expression of intersex in fish. This data is a crucial piece of 
information supporting numerous studies examining the biological consequences of CECs in the 
aquatic receiving environment.
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Chapter 1 - Introduction 
Over the last two decades it has become evident that a wide variety of chemicals are 
entering the environment that were not previously considered or assessed as environmental 
contaminants.  These contaminants of emerging concern (CECs) include pharmaceuticals, 
natural and synthetic estrogens, and industrial chemicals, encompassing an array of individual 
contaminants with varying modes of action (Daughton and Ternes 1999). Effluent discharges 
from municipal wastewater treatment plants (WWTPs) are a major source of CECs to the 
environment (i.e. Ternes 1998; Kümmerer 2001; Kolpin et al. 2002). Chronic exposure to low 
levels of CECs has been linked to adverse impacts in aquatic organisms worldwide (Jobling et al. 
1998; Mills & Chichester 2005). Although these impacts have been well documented, direct 
links between specific chemicals and effects observed in the environment are still not well 
established.   
Numerous studies have now documented the distribution of these CECs in wastewaters 
around the world, including Canada (Metcalfe et al. 2003; Servos et al. 2005; Lishman et al. 
2006). The influence of various treatment processes has been a very active area of research 
(Salveson et al., 2012). The composition of the final effluent is dependent on the inputs as well 
as the degree and type of effluent treatment (Joss et al. 2005; Clara et al. 2005; Salveson et al. 
2012). Although each treatment plant is unique, patterns are emerging that are helping to explain 
the distribution of CEC in final effluents released into the environment (Salveson et al. 2012). 
Many of these studies have been short term in nature and there has been limited characterization 
of wastewater effluents over longer periods (month-years) of time to capture variation in inputs 
to aquatic receiving environments.  The presence of CECs in effluents and associated receiving 
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environments, and their potential effects reported under laboratory settings means that they 
represent a potential risk to aquatic ecosystem health. Using two WWTPs that are undergoing 
major upgrades to the treatment process (Waterloo and Kitchener, ON), the current thesis 
examines how process changes and temporal variability impact the presence of CECs in 
municipal effluents. To characterize these effluents, changes in ammonia, nitrate, nitrite, selected 
pharmaceuticals as well as the total estrogenicity of the final effluent were examined over several 
years. This work supports several other ongoing studies on the impacts of wastewater effluents 
(and process upgrades) on fish responses in the Grand River, Ontario.  
1.1 CECs in wastewater effluents 
CECs have been reported in municipal wastewater effluents and associated surface 
waters worldwide (Pal et al. 2010; Petrie et al. 2014). Many of these compounds are human 
pharmaceuticals or natural estrogens that are not fully metabolized in the body and thus are 
excreted as waste (Escher & Fenner 2011; Vasquez et al. 2014). Other contaminants enter 
wastewater streams as byproducts of industrial or agricultural processes (Luo et al. 2014). A 
number of these contaminants are designed to be biologically active, and thus have the potential 
to impact non-target species in the receiving environment at low (ng/L to µ/L) concentrations 
(Fent et al. 2006; Arnold et al. 2014). Concentrations of CECs in effluent and the efficacy of 
their removal during conventional wastewater treatment vary widely depending on the properties 
of the individual contaminant as well as the treatment processes employed. As it is difficult to 
control the input of CECs to wastewater effluents, removal within the WWTP becomes a crucial 
step to limiting their presence in the environment. Improved understanding of CEC removal 
during treatment should therefore be of paramount concern, as both the input and removal 
efficacy of CECs is highly variable (Luo et al. 2014). An additional challenge to understanding 
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how these CECs behave is the accurate and precise quantification of contaminants at very low 
concentrations in complex matrices such as wastewater effluent. Significant work has been done 
since the early 1990s (and continues) to develop reliable and robust methodology for measuring 
these compounds in environmental samples.  
1.2 LC-MS/MS Analysis of CECs 
The detection and quantification of CECs in wastewater effluents is complicated by their 
low environmental concentrations, the wide variety of physiochemical properties, and the 
complexity of wastewater as a sample matrix. Although there is no standardized method for 
quantifying CECs in wastewater, extraction and analysis of these contaminants is frequently 
done with solid phase extraction (SPE) followed by liquid chromatography tandem mass 
spectrometry (LC-MS/MS). A comparison of analytical techniques found LC-MS/MS with 
isotope dilution was the most consistent method of analysis for the majority of CECs 
investigated (Vanderford et al. 2014). The use of LC-MS/MS typically provides sensitivity and 
accuracy when performing trace analysis on complex sample matrices. The addition of 
isotopically labelled standards compensates for matrix affects associated with co-extractives 
present in effluent samples. These methods typically use a deuterated version of the target 
analyte to account for extraction efficiencies and matrix effects that may occur during analysis. 
Development of a method for LC-MS/MS is a difficult task that requires the 
consideration of numerous processes that must be optimized for each target analyte. Although 
there are published methods for the evaluation of many CECs in wastewater effluents, some 
analytes, including estrogens, are more difficult to measure accurately and consistently at 
environmentally relevant concentrations. Method development for a new compound on LC-
MS/MS requires the consideration of a number of factors to ensure optimal sensitivity and 
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selectivity.  LC parameters, such as mobile phase, mobile phase gradient, and column, must be 
selected to sufficiently separate target analytes while minimizing run-time. At the source of the 
mass spectrometer, a number of parameters, including source gas temperature and flow must be 
considered to optimally ionize target analytes. Finally, the fragmenter voltage, collision energy, 
and cell accelerator voltage within the mass spectrometer must be optimized for each target 
analyte. Once these optimization steps are complete, the method must be validated for accuracy 
and precision, and the detection and quantitation limits must be determined. A continuing quality 
assurance and quality control (QA/QC) plan must then be implemented, at which point analysis 
of samples can begin. Notably, when working with such a complex matrix at such low 
concentrations of analyte, samples which pass robust QA/QC processes can still present with 
unusable or nonsensical data, often due to the incomplete separation of compounds at suitable 
resolution. Furthermore, chemical analyses typically employed, such as LC-MS/MS, allow 
researchers to quantify the concentration of known compounds within an effluent sample, but are 
limited in that they can only provide information on known chemicals for which analytical 
standards are available (Nadzialek et al. 2010). Additional techniques for evaluating effluents, 
including biological assays, can provide a compliment to analytical data and enhance 
understanding of effluent contamination.  
1.3 Biological assays for evaluation of effluent estrogenicity 
Biological assays are often used in tandem with chemical analysis to allow for a more 
thorough characterization of effluents. While chemical analysis with LC-MS/MS is excellent at 
quantifying the presence of known contaminants, it can only report on the subset of CECs that 
the method is designed to measure, and thus may exclude some contaminants that have the 
ability to impact aquatic biota in the receiving environment. Evaluating effluents with bioassays 
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is an approach to characterization of samples that considers the integrated response induced by 
the whole effluent rather than quantifying specific individual compounds. It is also desirable to 
use bioassays that are mechanistically linked to the effects in aquatic biota that are of concern. A 
number of cellular bioassays have been designed to measure the estrogenicity of environmental 
matrices such as wastewater effluents (Nadzialek et al. 2010). Leusch et al. (2010) compared five 
common estrogen assays (ER-CALUX, E-SCREEN, MELN, T47D0kBluc, YES), and found the 
responses were consistent across the assays, particularly between 0.2- 20 ng/L. When the Yeast 
Estrogen Screen (YES) and E-SCREEN assays were applied to the same samples in two different 
laboratories there was no significant difference in the data, indicating quality control/quality 
assurance may be able to minimize inter-laboratory variation (Leusch et al. 2010). The YES 
assay has a higher quantification limit than the other assays used but performed particularly well 
in highly polluted and complex samples (Leusch et al. 2010). 
The YES assay is a relatively straightforward and rapid way to determine the total 
estrogenicity of municipal wastewater treatment effluent (Nadzialek et al. 2010), and is often 
used in tandem with chemical analysis to characterize environmental samples (Beck et al. 2006; 
Viganò et al. 2008). This assay uses Saccharomyces cerevisiae yeast cells transfected with 
human estrogen receptor genes upstream of the β-galactosidase reporter gene (Gaido et al. 1997). 
These receptors are well conserved between species, allowing their activation in the YES assay 
(which is based on a human estrogen receptor) to indicate a similar response in exposed aquatic 
biota (Escher and Leusch 2012). After exposure to estrogenic compounds, the cells are 
suspended in a buffer that includes 2-nitrophenyl-β-D-galactosidase (ONPG), as well as 
compounds to induce cell lysis (Gaido et al. 1997). β-galactosidase will cleave ONPG to 
generate orthonitrophenol, and the resulting colour change can be measured with a microtiter 
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plate reader (Gaido et al. 1997). The relative speed and low cost of this assay paired with 
adequate sensitivity for determining estrogenic activity have made it a common tool for 
measuring estrogenicity in both wastewater and surface waters. 
1.4 Adverse impacts associated with CECs in wastewater effluents 
The ubiquitous presence of CECs in wastewater effluents has led to a large body of 
work investigating their potential impacts on aquatic life. Recent laboratory findings have 
demonstrated that chronic exposure to environmentally relevant levels of common 
pharmaceuticals can impact the metabolism, reproductive success, and development of fish 
(Ainter et al. 2009; David and Pancharatna 2009a; David and Pancharatna 2009b; Lister et al. 
2009; Galus et al. 2013a; Galus et al. 2013b; Luo et al. 2014; Schoenfuss et al. 2015). 
Zebrafish exposed to ibuprofen and acetaminophen have shown increased developmental 
abnormalities and increased mortality (David and Pancharatna 2009a; David and Pancharatna 
2009b), decreased spawning rates, and decreased clutch sizes (Lister et al. 2009). Galus et al. 
(2013a,b) found that adult female zebrafish exposed to four individual pharmaceuticals 
(carbamazepine, acetaminophen, venlafaxine, and gemfibrozil) as well as to a mixture of 
these pharmaceuticals produced fewer viable embryos and experienced increased oocyte 
atresia as well as altered kidney morphology. Likewise, the exposure of embryos to the same 
pharmaceuticals resulted in reduced survival and increased developmental abnormalities 
(Galus et al. 2013a,b). Goldfish exposed to the antidepressant fluoxetine exhibit altered 
behaviour, reproduction (Mennigen et al. 2008; Mennigen et al. 2010), and altered sex steroid 
levels (Mennigen et al. 2010). These findings indicate the potential for adverse impacts on 
fish exposed to wastewater effluents containing common pharmaceuticals.  
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More thoroughly documented are the adverse impacts associated with the natural and 
synthetic estrogens often found in wastewater effluents (Lange et al. 2001; Nash et al. 2004; 
Schäfers et al. 2007; Parrott & Blunt 2005; Kidd et al. 2007). These CECs act as estrogen 
receptor agonists and have the potential to impact aquatic life at very low (>1 ng/L) 
concentrations. Many studies have reported changes in the reproductive system or fitness of 
wild fish downstream of WWTP outfalls (Jobling et al. 1998; Woodling et al. 2006; Hinck et 
al. 2009; Tanna et al. 2013), and recent work has demonstrated that secondary-treated 
municipal effluents have the potential to cause changes in fish and fish populations in 
receiving environments (e.g. Tyler et al. 2008; Tetreault et al. 2011; 2013). Of particular note 
is the occurrence of intersex and changes in reproductive performance in fish associated with 
these wastewater effluent outfalls (Bahamonde et al. 2013; Sumpter & Jobling 2013); these 
changes may have associated impacts at the population levels (Tetreault et al. 2011; Fuzzen et 
al. 2015).  In a whole lake experiment, Kidd et al. (2007) found exposure of fathead minnows 
(Pimephales promelas) to 5 – 6 ng/L of 17α-ethinylestradiol (EE2) resulted in feminized male 
fish with arrested gonadal development, which within two years led to recruitment failure in 
the population. These observations suggest that very low levels of EDCs in the environment 
can have adverse effects on exposed fish, and removal of these compounds from effluents 
should be an area of concern for environmental decision-makers. 
1.5 Removal of CECs from wastewater  
Although removal through treatment is crucial to limiting the entry of CECs into the 
environment, effluent quality monitoring does not typically include the analysis of these 
contaminants. Traditional measures of effluent quality focus instead on indicators such as 
total suspended solids, nutrient loading, and biological oxygen demand. Although these 
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indicators are important parameters to assist in the mitigation of environmental impact, they 
fail to account for the presence of CECs at trace (ng/L or g/L) levels. No current Canadian 
legislation exists to specifically address these contaminants, and thus removal is dependent on 
processes implemented to meet conventional targets. 
As wastewater treatment plants are not intentionally designed to remove CECs, removal 
efficacy varies between individual contaminants and treatment processes (Nakada et al. 2006; 
Salveson et al. 2012; Luo et al. 2014). Chemical processes, such as hydrolysis, volatilization, and 
photolysis, can also be important for the removal of some chemicals. However, these processes 
are generally responsible for very little CEC removal during conventional wastewater treatment. 
Sorption and biotransformation are the primary mechanisms for the removal of CECs from 
municipal wastewater (Salveson et al. 2012; Luo et al. 2014).  Sorption is the process by which 
CECs are removed from wastewater through complexing with organic solid waste due to 
hydrophobic or electrostatic interactions (Salveson et al. 2012). Sorbable CECs are often 
hydrophobic, though the properties of the sludge in the system (e.g. organic content, charge) can 
also modify removal (Hyland et al. 2012). This is demonstrated by removal due to electrostatic 
interactions between negatively charged activated sludge and CECs that are positively charged at 
sludge pH (Jelic et al. 2012), indicating that estimation of a compound’s sorption potential must 
consider both its hydrophobicity and its ionization state (Salveson et al. 2012). Historically, a 
compound’s log Kow value (octonal-water partitioning coefficient) was used to estimate sorption 
to sludge. However, this metric does not account for the altered sorption potential of weakly 
acidic or basic compounds in different ionization states. A pH-dependent partitioning coefficient 
(log Dow) is a more accurate metric to estimate sorption potential for ionizable compounds 
(Salveson et al. 2012). However, the use of these metrics provides only a broad estimation of 
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sorption potential. To accurately assess the sorption of a CEC in a WWTP, the compound must 
be investigated within that particular system (determination of specific partition coefficients, Kp). 
This is in part due to the differences in the structure and properties of the organic matter in each 
matrix.  
Biotransformation is the removal through biological processes and can be estimated 
based on a CEC’s physiochemical properties and verified through laboratory assays (Salveson et 
al. 2012). Biodegradation potential can be represented by a first-order kinetic rate that is 
calculated for each specific compound in a particular sludge, and can vary widely between 
different processes (Salveson et al. 2012).The biodegradability of a compound is dependent on 
factors such as its physical structure (chain length or branching), size, and solubility, as well as 
process characteristics (Salveson et al. 2012). CECs that readily degrade in wastewater systems 
tend to be soluble in water, smaller, and have sites amenable to biological attack, though these 
metrics provide only a broad generalization with which removal efficacy may be estimated. The 
degree of removal achieved by sorption and biotransformation for any CEC is thus driven by a 
combination of the CEC’s physiochemical properties and by the treatment processes it 
undergoes. Considering the number of chemicals and the diversity of treatment processes it is 
difficult to predict the composition of final wastewater effluents. Despite this complexity some 
general patterns have emerged from the literature. Although each treatment plant can vary 
considerably in design, they generally follow similar processes, and must meet similar legislated 
targets for effluent quality. 
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Table 1.5.1. Some physical and chemical properties of selected CECs.  
Adapted from “Hazardous Substances Data Bank” by United States National Library of Medicine. aNakamura et al. 2008 bAdlard et 
al. 1995  c Trenholm et al. 2006 d(Petrie et al. 2014) e(Zhang et al. 2008) f(Clara et al. 2004) g(Salveson et al. 2012)
Class Compound Most Common Use Chemical Formula Molecular Weight 
(g/mol) 
pKa Log Kow Log Dow at pH 7g 
Antiandrogens Triclosan Personal care products C12H7Cl3O2 289.54 7.9 4.76 4.9 
 Triclocarban Personal care products C13H9Cl3N2O 315.58 12.7d 4.2d 4.93 
Antibiotics Sulfamethoxazole Veterinary medicine C10H11N3O3S 253.28 pKa 1 = 1.6 
pKa 2 = 5.7 
0.89 0.14 
 Trimethoprim Veterinary medicine C14H18N4O3 290.32 7.12 0.91 0.92 
Anti-epileptics Carbamazepine Anti-epileptic C15H12N2O 236.27 13.9 2.45 2.5 
Estrogens 17α-ethynylestradiol  Birth Control Pill C20H24O2 296.40 10.7f 4.2 3.81 
 17β-estradiol Natural Hormone C18H24O2 272.38 10.4c 4.1 3.75 
 Estrone Natural Hormone C18H22O2 270.36 10.4c 4.0 4.31 
 Estriol  Natural Hormone C18H24O3 288.38 10.4c 3.13 2.67 
Fibrates Gemfibrozil Hypolipidemic C15H22O3 250.33 4.5 4.77 1.85 
NSAIDS Diclofenac Anti-inflammatory C14H22O 296.16 4.15e 4.51g 1.37 
 Ibuprofen Anti-inflammatory C13H18O2 206.29 5.2 3.97 1.71 
 Naproxen Anti-inflammatory C14H14O3 230.25 4.15 3.18 0.25 
SSRIs Fluoxetine Antidepressant C17H18F3NO 309.33 10.1a 4.05b 1.5 
SNRIs Venlafaxine Antidepressant C17H27NO2 277.40 10.09 3.2 2.77 
Statins Atorvastatin Lowering blood cholesterol C33H35FN2O5 558.64 4.46   
 p-hydroxy Atorvastatin Atorvastatin metabolite C33H34FN2O6 573.65    
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Primary treatment typically consists of the removal of suspended solids and some organic 
materials through the use of settling tanks and skimmers (Metcalfe and Eddy 2003). In some 
cases, a chemical coagulant may be used to improve sedimentation (Metcalfe and Eddy 2003). 
As this stage of treatment is primarily concerned with the settling out and removal of solids, 
CECs that are highly sorbable can show removal during this stage of treatment, while those that 
have low sorption potential show little to no removal (Salveson et al. 2012).  
Secondary treatment uses biological and chemical agents to remove organic material and 
nutrients from wastewater. This is the stage of treatment that most influences CEC removal from 
wastewater, and is also the stage that shows the highest process variability among WWTPs. In 
Canada, conventional activated sludge (CAS) systems are the most common type of secondary 
treatment in municipal WWTPs (Canadian Water and Wastewater Association 2001). These 
systems are designed to remove organic contaminants through metabolic degradation by 
biological organisms followed by sedimentation in secondary clarifiers. Within a CAS system, 
operational parameters, such as temperature, hydraulic retention time (HRT), solids retention 
time (SRT) and redox conditions, result in varied bacteria communities and degrees of 
nitrification, which have a significant impact on CEC removal (Salveson et al. 2012; Luo et al. 
2014).  
Nitrifying conditions (ammonia conversion to nitrate) in WWTPs has been shown to 
improve removal efficacy for a number of CECs, including natural and synthetic estrogens 
(Servos et al. 2005; Suarez et al. 2010; Fernandez-Fontaina et al. 2012; Luo et al. 2014). 
Improved removal in nitrifying systems is particularly pronounced for compounds that are 
readily biotransformed, such as ibuprofen and naproxen (Suarez et al. 2010; Fernandez-Fontaina 
et al. 2012; Arlos et al. 2014). This could be due to the chemical conditions and/or the specific 
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bacterial communities present. Nitrification typically occurs alongside an increased SRT, 
resulting in a more diverse bacterial community that can more readily remove easily degradable 
compounds. CECs that are not readily biotransformed, including carbamazepine, tend to show 
little removal in conventional treatment plants even with nitrifying treatment (Salveson et al. 
2012). The properties that make these compounds difficult to degrade still complicate 
degradation even when exposed to a more diverse bacterial community. As a result, improved 
removal efficacy under nitrifying conditions does not typically extend to recalcitrant compounds 
(Suarez et al. 2010; Fernandez-Fontaina et al. 2012; Luo et al. 2014).  
As previously noted, the implementation of nitrification typically requires an extended 
SRT, allowing for the cultivation of a more diverse bacterial community. Literature surrounding 
the impact of SRT on removal of CECs indicates that it is compound and process dependent. 
Numerous studies have reported that increased SRTs resulted in improved removal efficacy for a 
broad range of micropollutants (Metcalfe et al. 2003; Servos et al. 2005; Clara, Strenn, et al. 
2005; Suarez et al. 2010; Salveson et al. 2012), while others have found no correlation between 
SRT and CEC removal (Joss et al. 2005; Samaras et al. 2013). Salvenson et al. (2012) reported 
threshold SRT values for a number of compounds. When these SRTs were met or exceeded, 80% 
removal of the target CEC was achieved in their system (Salveson et al. 2012). These values 
ranged from 5 d for readily biotransformed CECs like ibuprofen and naproxen up to 30 d for 
trimethoprim. No threshold SRT could be determined for the most highly recalcitrant compounds 
such as carbamazepine. Servos et al. (2005) in a survey of Canadian WWTPs found that SRT > 5 
d resulted in the effective removal of estrogenic compounds as well as effluent estrogenicity. As 
part of the same study, Metcalfe et al. (2003) found an SRT of  > 5 d resulted in the removal of 
many, but not all, pharmaceuticals studied. Although the mechanism is unclear, increased SRT, 
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which is typically associated with better treatment, is frequently correlated with reduced release 
of a variety of CECs, though some contaminants remain very recalcitrant in final effluents. 
Although all plants in Canada are now required to implement secondary treatment processes (or 
equivalent), the conditions and operation may differ greatly leading to very different removal 
rates of CECs. 
Tertiary treatment of various forms is often employed to further improve effluent quality 
to achieve desired receiving water quality. This type of advanced treatment is frequently 
employed when specific contaminants of concern are identified in influents or effluents. Tertiary 
treatment targeting CECs through the use of advance oxidation processes like UV:hydrogen 
peroxide and ozonation, are a current area of active research. Although UV light alone has 
minimal effect on most CEC, in combination with hydrogen peroxide it can be very effective at 
removing many CECs (Ternes et al. 2003; Rosario-Ortiz et al. 2010; Cesaro & Belgiorno 2015) 
Ozonation has been shown to successfully remove a number of CECs through oxidation, 
including those that are typically difficult to remove with conventional treatment processes 
(Prasse et al. 2015). The success of ozonation is dependent on dose as well as characteristics of 
the wastewater such as pH and organic matter content (Prasse et al. 2015). The primary concerns 
surrounding these methods of treatment are their high cost as well as the potential for the 
formation of reactive byproducts (Prasse et al. 2015; Semblante et al. 2015). 
Overall, rapidly biotransformed CECs with low sorption potential typically have high 
removal efficacies, particularly in treatment plants with nitrifying treatment and SRTs above 5-7 
days (Clara et al. 2005; Servos et al. 2005; Nakada et al. 2006; Salveson et al. 2012). In contrast, 
CECs that are resistant to biological transformation are more recalcitrant unless advanced 
processes are used, e.g. advanced oxidation (Salveson et al. 2012). Compounds with moderate 
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biotransformation vary widely in their removal depending on the operating parameters of the 
plant, with nitrification and increased SRTs typically associated with improved removal 
(Fernandez-Fontaina et al. 2012; Salveson et al. 2012). CEC removal also has been found to vary 
seasonally, with increased removal efficacy in summer and reduced efficacy in winter (Salveson 
et al. 2012). In Canada, where temperature can vary considerably throughout the year, treatment 
efficiencies, (e.g. nitrification) may be very important (Parker et al. 2014). As removal of CECs 
in wastewater treatment is a byproduct of processes intended to meet legislated targets, it is 
likely that CECs, particularly those resistant to biological transformation, will persist in 
effluents. It is therefore important to understand potential impacts to aquatic life in the receiving 
environment associated with chronic, low level exposure to CECs.   
1.6 Wastewater effluents in the Grand River watershed 
CECs have been detected in municipal wastewater effluents across Canada (Metcalfe et 
al. 2003; Servos et al. 2005; Lishman et al. 2006), including in the Grand River watershed 
(Tanna et al. 2013; Arlos et al. 2014). The Grand River is a highly impacted watershed, and 
receives inputs from more than 30 WWTPs (Chapman & Anderson 2011). Antimicrobials, 
antiandrogens, estrogens, artificial sweeteners, polycyclic musks and numerous pharmaceuticals 
have all been associated with major WWTP outfalls in the central Grand River (Servos et al. 
2005; Smyth et al. 2008; Metcalfe et al. 2010; Spoelstra et al. 2013; Arlos et al. 2014; Couperus 
et al. 2016). Numerous studies evaluating impacts associated with these effluent outfalls in the 
Grand River have focused on the rainbow darter (Etheostoma caeruleum), a small-bodied 
benthic fish found throughout the watershed. When exposed to wastewater effluent in the Grand 
River, rainbow darter have exhibited effects at multiple levels of biological organization, 
including impacts often associated with EDCs. Rainbow darter present at sites downstream of 
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wastewater treatment plants in the Grand River have been found to have altered gene expression, 
sex steroid levels, gonad size and expression of elevated rates of intersex (testis-ova) associated 
with wastewater outfalls (Tetreault et al. 2011; Tanna et al. 2013; Bahamonde et al. 2015). 
Downstream of the Kitchener WWTP outfall, 80 – 100% of fish captured between 2009 and 
2011 exhibited intersex (Tetreault et al. 2011; Tanna et al. 2013; Bahamonde et al. 2015). In 
addition, there is evidence that suggests changes in reproductive performance (Fuzzen et al. 
2015) and altered fish assemblages (Tetreault et al. 2013). These changes may be related to a 
variety of contaminants found in the effluents including estrogenic and/or antiandrogenic 
compounds present in the wastewater effluent. 
The Region of Waterloo is currently upgrading both the Waterloo (Table 1.6.1) and 
Kitchener (Table 1.6.2) WWTPs in order to improve effluent quality (Bicudo et al. 2016). 
Previous studies following municipal treatment plant upgrades in Boulder, Colorado showed that 
treatment upgrades (moving from trickling filters and solid contact to activated sludge) reduced 
effluent estrogenicity, and corresponding impacts, such as intersex, in fish downstream of the 
outfall (Barber et al. 2012). Prior to upgrades, the Kitchener and Waterloo WWTPs operated as 
secondary conventional activated sludge plants with minimal or no nitrification.
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Table 1.6.1 Characteristics of the Waterloo WWTP  
Treatment Plant Waterloo – Pre Waterloo – Post (anticipated) 
Treatment Capacity Rate (m3/d) 57,500 57,500 
Treatment System Conventional activated sludge (partial/non-
nitrifying) 
Conventional activated sludge (partial/non-
nitrifying) 
Primary Treatment Bar screen, grit removal, primary clarifier Bar screen, grit removal, primary clarifier 
Secondary Treatment Conventional activated sludge 
 
Conventional activated sludge with return 
activated sludge 
 
Advanced Treatment Phosphorous removal Phosphorous removal 
Disinfection Sodium hypochlorite UV light 
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Table 1.6.2. Characteristics of the Kitchener WWTP before and after upgrades. 
Treatment Plant Kitchener – Pre Kitchener – Post (Current status) 
Treatment capacity rate 
(m3/d) 
122,000 122,000 
Treatment System Convectional activated sludge (non-nitrifying) Convectional activated sludge (fully nitrifying) 
Primary Treatment Bar screen, grit removal, primary clarifier Bar screen, grit removal, primary clarifier 
Secondary Treatment Conventional activated sludge1 Conventional activated sludge3 with return 
activated sludge 
 
Advanced Treatment Phosphorous removal Phosphorous removal 
Disinfection Sodium hypochlorite UV light 
Notes 2Two secondary treatment trains; shared headworks, 
primary clarifier; trains re-join before 
chlorination/dechlorination 
4Two secondary treatment trains; shared 
headworks, primary clarifier; trains re-join before 
UV disinfection  
1 Mechanical surface aeration 
2 Both secondary treatment trains were operating as fully mixed bioreactors 
3 Fine bubble aeration installed in August 2012 (75% of the aeration tanks) and January 2013 (100% of aeration tanks); returning centrate passes 
through re-aeration zone 
4 Train 1 operating as a fully mixed bioreactor; Train 2 operating as a three-pass plug flow train as of Fall 2012
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Upgrades at the Kitchener and Waterloo WWTPs began in 2007 and are scheduled to be 
completed in 2018 (Bicudo et al. 2016). At both plants, upgrades will move treatment towards 
extended solids retention times, nitrification, and UV disinfection of the effluents which is 
expected to greatly improve their quality. The Region of Waterloo’s target for ammonia exiting 
the Kitchener WWTP is 7 mg/L year-round after the upgrades that occurred in 2012 and 2013, 
and 2 – 5 mg/L when all upgrades are completed in 2018 (Figure 1.6.1), far below the 
approximately 28 mg/L documented in effluents prior to upgrades (Bicudo et al. 2016).  
The most significant upgrade impacting CEC removal at the Kitchener WWTP between 
2007 and 2015 was the improvement to secondary treatment in late 2012 and early 2013 (Figure 
1.6.1). The configuration of train 2 was altered from a completely mixed bioreactor to a three-
step plug-flow system with a re-aeration zone for the return activated sludge entering the system 
(Bicudo et al. 2016). This change, paired with an upgrade from mechanical surface aeration to 
fine bubble aerators in both trains, allowed for a longer, stable SRT (an increase from <2 days to 
5.4 days) and the growth of more diverse bacterial communities, resulting in nitrifying treatment 
in both treatment trains (Bicudo et al. 2016). In addition, these improvements increased the 
capacity of the secondary clarifiers (Bicudo et al. 2016).  
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Figure 1.6.1 Broad timeline of upgrades at the Kitchener WWTP adapted from Region of 
Waterloo (2010). UVDF = UV disinfection, EPS = Effluent pumping station. 
 
The upgrades at the Waterloo WWTP, including major upgrades to include additional 
aeration to achieve nitrification, were originally expected to be completed in the fall of 2014 but 
have experienced delays in construction. The targeted upgrades were similar to those at the 
Kitchener WWTP, including implementation of a three-pass plug-flow system with fine bubble 
aeration for secondary treatment of effluents. Construction was halted after UV disinfection and 
return activated sludge processes were implemented but before improvements to aeration were 
made, resulting in high ammonia loading in the effluents (Figure A4.2). In mid-2014 a re-
aeration zone was added for the return activated sludge (RAS) process, but the aeration in the 
rest of the secondary treatment train was not upgraded.  
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  Previous work in the Grand River watershed indicated that treatment plants with greater 
nitrification led to greater removal of CECs (Tanna et al. 2013; Arlos et al. 2014). A number of 
ongoing studies in the Grand River watershed are working to characterize fish response to these 
changes in treatment on numerous levels of biological organization. An evaluation of impacts 
requires knowledge of what the organisms in the affected sites are exposed to. Wastewater 
effluents are extremely complex matrices, and their makeup varies significantly depending on 
the inputs to and processes employed within the plant. Effluents exiting a WWTP can also vary 
seasonally or due to process upsets. As a result of this variation, proper characterization of 
exposure requires a thorough understanding of the effluents exiting the WWTP upstream of 
impacted sites, and cannot be generalized from other WWTPs. As a result, it is imperative to 
characterize the specific effluents affecting an impacted site, and to understand their temporal 
variability.   
1.7 Study Objectives 
This study was intended to support the interpretation of biological work occurring 
downriver of the Kitchener and Waterloo WWTPs by providing data on potential exposure. 
Using two WWTPs undergoing major upgrades to the treatment process (Kitchener and 
Waterloo WWTPs), the current study examines how process upgrades and temporal variability 
impact the concentration of CECs in municipal effluents through: 
1. Analysis of select CECs with LC-MS/MS in historical and current effluent samples. 
2. Analysis of total estrogenicity in historical and current effluent samples via the YES 
assay. 
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1.8 Study Scope 
To characterize the effluents of the Kitchener and Waterloo WWTPs over time, 
monthly grab samples of effluent were analyzed alongside limited archived samples for 
fifteen pharmaceuticals, three estrogens, and total estrogenicity.  
Wastewater effluents may contain hundreds of CECs with widely varying 
physiochemical characteristics. The number of CECs selected for analysis must be therefore 
limited for practical reasons while still accurately characterizing the wastewater effluent. One 
way CECs can be categorized is by separation into broad categories based on the mechanisms by 
which they are removed in wastewater treatment (Salveson et al. 2012). A suite of indicator 
compounds was designed to allow for the evaluation of a broad spectrum of removal efficacy by 
sorption and biotransformation (Salveson et al. 2012). This allows for more general 
characterization of a WWTP’s removal efficacy for CECs with similar physical and chemical 
properties (Salveson et al. 2012).  The final consideration in the selection of CECs was the 
presence of a robust methodology and instrumentation for analysis and quantitation (Table 
1.8.1). This was to ensure the data provided were accurate, precise, and sufficiently sensitive for 
environmental relevance.  
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Table 1.8.1 Selected CECs and their categorization based on expected mechanisms of removal in 
wastewater treatment. 
  Biotransformation Potential 
 Level Low Medium High 
S
o
rp
ti
o
n
 P
o
te
n
ti
a
l 
Low Carbamazepine 
Diclofenac 
Sulfamethoxazole 
Trimethoprim 
Gemfibrozil 
Venlafaxine 
 
Ibuprofen 
Naproxen 
 
Medium  17-α ethinylestradiol 
Atorvastatin 
 
Estradiol 
Estrone 
High Triclocarban  Triclosan 
Fluoxetine 
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Chapter 2 -  Materials and Methods 
2.1 General Approach 
Archived sample extracts of effluent from the Kitchener and Waterloo WWTPs in 2010, 
2011, 2012, and 2013 were analyzed for CECs and estrogenic potency alongside effluent 
samples taken monthly from September 2014 to September 2015. Corresponding water quality 
data was collected at each effluent sampling (ammonia, nitrate, nitrite, chloride, conductivity). 
Samples were analyzed for select CECs with two LC-MS/MS methods and total estrogenic 
potency with the YES assay.  
2.2 Materials 
All solvents were of high performance liquid chromatography (HPLC) grade or higher. 
Methanol (MeOH), acetonitrile (ACN), ethyl acetate, and 10 M hydrochloric acid were 
purchased from Fisher Scientific (Toronto, ON, Canada). Methyl tert-butyl ether (MTBE), 
ammonium fluoride, and ammonium acetate were obtained from Sigma-Aldrich (Oakville, ON, 
Canada). Ultrapure water for mobile phase preparation was obtained from an EMD Milli-Q® 
Advantage A10 water purification system (Etobicoke, ON, Canada).  
Atorvastatin and its metabolites, carbamazepine, diclofenac, fluoxetine, gemfibrozil, 
ibuprofen, naproxen, sulfamethoxazole, triclocarban, trimethoprim, venlafaxine, 4-nonylphenol, 
4-octylphenol, estrone, 17α-ethynylestradiol, 17β-estradiol, estriol, lorazepam, and 
chloramphenicol were purchased from Sigma-Aldrich. Triclosan was purchased from Alfa Aesar 
(Wardhill, MA, USA). The isotopically labelled standards atorvastatin-d5, p-hydroxy 
atorvastatin-d5, carbamazepine-d10, diclofenac-d4, fluoxetine-d5, gemfibrozil-d6, ibuprofen-d3, 
naproxen- d3, sulfamethoxazole-d4, triclosan-d3, trimethoprim-d3, triclocarban-d4, venlafaxine-d6, 
estrone-d4, estriol-d2, 17α-ethynylestradiol-d4, 17β-estradiol-d4, bisphenol A-d16, 4-nonylphenol-
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d4, 4-octylphenol d-17, and metformin-d6 were purchased from CDN Isotopes Inc. (Pointe-Claire, 
QC, Canada). Stock solutions of all compounds were prepared in methanol. 
Yeast β-galactosidase assay kits were purchased from ThermoFisher Scientific 
(Markham, ON, Canada). All other reagents for use in the YES assay were purchased from 
Sigma-Aldrich (Oakville, ON, Canada). A full list of these reagents can be found in Appendix 
A2: Reagents required for the YES Assay.  
2.3 Wastewater Effluent Sampling 
Grab samples were collected in triplicate directly from the effluent outflow just prior to 
release into the river at the Kitchener and Waterloo WWTPs. Samples were collected in pre-
cleaned amber glass bottles with Teflon-lined screw caps and preserved with 1 g/L sodium azide 
and 50 mg/L ascorbic acid to prevent bacterial growth and analyte degradation. Samples were 
stored at 4 °C until extraction, usually within 24 h but always within 48 h of collection. Samples 
collected for LC-MS/MS analysis were taken in 125 mL bottles, while samples collected for 
analysis via the YES bioassay were taken in 500 mL bottles. 
For analysis of nutrient data (ammonia, nitrite, nitrate), 250 mL grab samples were 
collected in triplicate in high density polyethylene (HDPE) bottles with 1 mL of 49% sulfuric 
acid as a preservative. For analysis of chloride and conductivity, 250 mL grab samples were 
collected in triplicate without preservation in 250 mL HDPE bottles. 
2.4 Sample Preparation and Solid Phase Extraction 
2.4.1 Solid Phase Extraction 
Wastewater effluent samples were analyzed for select CECs with two LC-MS/MS 
methods as well as total estrogenicity with the YES assay. Three solid phase extraction (SPE) 
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methods were used, each optimized for the target analytes. The three solid phase extraction 
methods used are outlined in Table 2.4.1. 
All samples were filtered through a glass fiber filter with a pore size of 1 µm (Pall 
Corporation, Mississauga, ON) prior to extraction. Isotopically labelled standards for each target 
CEC were added to samples prior to extraction for analysis with LC-MS/MS. Samples for 
bioassays were not spiked. A ThermoFisher AutoTrace™ (Dionex, Sunnyvale, CA) was used to 
extract the samples. All cartridges were preconditioned with solvents followed by water, and 
samples were passed through at a rate of approximately 5 mL/min. After elution, samples were 
evaporated to dryness under a gentle stream of nitrogen using a ThermoFisher SE 500 solvent 
evaporator at 30°C (Dionex, Sunnyvale, CA). After extraction, samples were stored at -20°C 
until analysis. 
26 
 
 
Table 2.4.1. Three SPE methods for the optimized extraction of different target analytes from wastewater effluents. 
Target  Cartridge Volume 
extracte
d (mL) 
Isotopically labelled 
surrogates (µg/L) 
pH 
Adjustment 
Wash Elution Reconstitution 
Pharmaceuticals
, personal care 
products 
(PPCP) 
Bond Elut 
Plexa1 
100 20 To pH 2.0 ± 0.5 
with 10 M HCl 
5 mL water 
5 mL 5% MeOH in water 
3 mL MeOH 
3 mL MeOH 
500 µL MeOH with 75 
µg/L lorazepam and 
chloramphenicol 
Estrogenic 
Potency 
Oasis 
HLB2 
500 None used None 5 mL water 
 
5 mL 10:90 
MeOH:MTBE  
5 mL MeOH 
80 µL MeOH 
Estrogens Superclean 
LC-183 
100 20 None 5 mL water 
5 mL hexanes 
5 mL ethyl acetate 
5 mL ethyl acetate 
500 µL MeOH with 75 
µg/L lorazepam and 
chloramphenicol 
1Bond Elut Plexa cartridges (6 cc, 500 mg, Agilent Technologies, Mississauga, ON) 2 Oasis HLB cartridges (6cc, 500 mg, Waters, Milford, MA) 3 
Superclean LC-18 cartridges (6cc, 500 mg, Sigma-Aldrich) 
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2.4.2 Solid Phase Extraction Quality Assurance and Quality Control 
With each batch of samples three quality assurance/quality control (QA/QC) samples 
were processed; one negative control (blank) and two positive controls (MS1, MS2). All three 
QA/QC samples were prepared in MilliQ water. The blank was spiked with only isotopically 
labelled standards. The positive controls MS1 and MS2 are identical replicates spiked with both 
isotopically labelled standards and unlabeled chemicals at a concentration of 20 µg/L. As of 
February 2015, additional wastewater matrix QA/QC samples were added to the monthly 
extractions, spiked with both isotopically labelled standards and unlabeled chemicals at a 
concentration of 20 µg/L. These additional QA/QC samples help to account for matrix effects as 
well as to determine the efficiency of the extraction procedure.  
2.5 Sample Analysis 
2.5.1 LC-MS/MS analysis of select pharmaceuticals and personal care products 
Analysis of pharmaceutical samples extracted with Bond Elut Plexa was performed with 
liquid chromatography and tandem mass spectrometry (LC-MS/MS). Separation of analytes was 
completed on an Agilent 1200 HPLC (Agilent, San Pedro, CA) using a 4.6 mm x 150 mm x 5 
μm Agilent Eclipse XDB-C18 column. Detection of analytes was completed using multiple 
reaction monitoring (MRM) on a Sciex 3200 QTRAP mass spectrometer (ABSciex, Concord, 
ON, Canada) with electrospray ionization (ESI). Samples were run in both positive and negative 
ion mode to identify all target analytes. Analytes were identified based on the transitions listed in 
Table 2.5.1. Source-dependent and compound-specific parameters are listed in Appendix A, 
Table A1.1. The mobile phases used for this analysis were 5 mM ammonium acetate in MilliQ 
water (A) and 100% methanol (B). The mobile phase gradient was dependent on which ion mode 
was selected. For positive ion mode, the mobile phase gradient began at 50% B, increased to 
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100% B over 7.5 min, and was then held at 100% B for 2 min. In negative ion mode, the mobile 
phase gradient began at 40% B, increased to 100% B over 7.5 minutes, and was then held at 
100% B for 3 min. In both cases, a re-equilibration period of 5 minutes occurred after each 
sample to return the mobile phase gradient to starting conditions. 
Table 2.5.1 Parameters for analysis of select PPCPs 
Analyte  Q1  Q3  Polarity  
Atorvastatin 559.3 440.2 Positive 
p-hydroxy atorvastatin 575.2 440.3 Positive 
Carbamazepine 237.1  193.3  Positive 
Diclofenac 293.9 250 Negative 
Fluoxetine 310.3 44.3 Positive 
Gemfibrozil 249.1 121.1 Negative 
Ibuprofen 204.9  160.9  Negative 
Naproxen 229.0  170.0  Negative 
Sulfamethoxazole 254.1 156.2 Positive 
Triclocarban 314.8 161.6 Negative 
Triclosan 286.9  35.0  Negative 
Trimethoprim 291.1 261.2 Positive 
Venlafaxine 278.3 58.1  Positive 
Surrogate Q1  Q3  Polarity  
Atorvastatin-d5 564.3 445.3 Positive 
p-hydroxy atorvastatin-d5 580.2 445.2 Positive 
Carbamazepine-d10 247.2 204.4 Positive 
Diclofenac-d4 298.2 253.8 Negative 
Fluoxetine-d5 315.2 44.2 Positive 
Gemfibrozil-d6 255 120.7 Negative 
Ibuprofen-d3 207.9 164.1 Negative 
Naproxen-d3  232.1  172.8  Negative 
Sulfamethoxazole-d4 258.1 160.1 Positive 
Triclocarban-d4 316.9 159.9 Negative 
Triclosan-d3  286.9  35.0 Negative 
Trimethoprim-d3 294.2 230.3 Positive 
Venlafaxine-d6 288.4 58.1 Positive 
Q1=quadrupole 1; Q3=quadropole 3 
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2.5.2  LC-MS/MS analysis of selected estrogens 
Analysis of select estrogens extracted with Superclean LC-18 was performed with LC-
MS/MS. Separation of analytes via liquid chromatography was completed on an Agilent 1260 
HPLC with a 2.1 mm x 50 mm x 1.8 μm Agilent ZORBAX Eclipse Plus C18 column. Detection 
of analytes was completed using dynamic multiple reaction monitoring (dMRM) on an Agilent 
6460 triple quadrupole (QQQ) mass spectrometer with Agilent Jet Stream (AJS) electrospray 
ionization. Samples were run in both negative ion mode to identify all target analytes. Analytes 
were identified based on the transitions listed in Table 1.5.2. Source-dependent and compound-
specific parameters are listed in Appendix A, Table A1.2.  
The mobile phases used for this analysis were 0.5 mM ammonium fluoride in MilliQ 
water (A) and 100% acetonitrile (B). The mobile phase gradient started at 10% B, increased to 
100% B over 10 minutes, and was then held at 100% B for 3 minutes. An 8 minute re-
equilibration period occurred after each sample to establish the mobile phase gradient at its 
starting conditions. 
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Table 2.5.2. Parameters for the analysis of select estrogens via LC-MS/MS 
Analyte  Q1 Q3 Polarity  
Bisphenol A 227.3 133.2 Negative 
  212.3 Negative 
Estrone 269.4 145.1 Negative 
  143.1 Negative 
Estradiol 271.4 145.1 Negative 
  143.1 Negative 
Estriol 287.4 171.2 Negative 
  145.1 Negative 
Ethinylestradiol 295.39 158.9 Negative 
  144.9 Negative  
Triclosan 286.99 35 Negative 
Surrogate Q1 Q3 Polarity  
Bisphenol A - d16 241.28 223.3 Negative 
  142.2 Negative 
Estrone - d2 271.2 147.1 Negative 
  145.1 Negative 
Estrone-d4 273.4 147.1 Negative 
  145.1 
Negative 
Estradiol-d4 275.2 187.2 Negative 
  145.3 Negative 
Estriol-d2 289.39 173.2 Negative 
  147.1 Negative 
Estriol-d3 290.2 173.2 
Negative 
  145.3 Negative 
Ethinylestradiol - d4 299.4 161.2 Negative 
  147.2 Negative 
Triclosan-d3 289.99 35 Negative 
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2.5.3 Measuring estrogenic potency with the YES assay 
Analysis of the total estrogenicity of samples extracted with the Oasis HLB method was 
performed with the YES assay. Buffers and other materials for the YES assay were prepared as 
outlined in Appendix A2: Reagents required for the YES Assay, Table A2.1. 
Saccharomyces cerevisiae cells (Receptor: ERtrp (YePtrpER), Reporter E2.ura 
(YRpE2ura)) provided by Heidi Engelhardt, University of Waterloo (originally from K. Gaido, 
Research Triangle Park) were stored in 30% glycerol stock at -80°C until use. After thawing at 
4°C, cells were streaked on agar plates and placed in a 30°C incubator at 300 rpm for 3-4 days, 
or until identifiable colonies were present. Plates were then stored at 4°C until use for no more 
than 14 d. 
A single yeast colony was selected from the agar plate, placed into 1 mL GOLD media in 
a 25 mL centrifuge tube, and incubated at 30°C and 300 rpm for 24 h. Cells were then diluted 
1:10 in minimal media and incubated at 30°C and 300 rpm for 24 h. After 24 h, cells were 
diluted 1:1 in minimal media and incubated at 30°C and 300 rpm for 6 h. When the incubation 
period was complete, cells were diluted in minimal media and 50 µM copper sulfate to an optical 
density (OD) of 0.03 at 660 nm.  
Standards or samples were transferred in 10 µL aliquots in duplicate into 2 mL amber 
glass vials and left open in the flow hood to dry. Three pseudoreplicates from each annual 
sampling event were run in duplicate in a 2x serial dilution curve in MeOH from undiluted 
effluent to 1024x dilution. Once the sample or standard was dry, 200 µL of the cells in minimal 
media and copper sulfate was added to each vial. Vials were capped and incubated for 18 - 24 h 
at 30°C and 300 rpm. 
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After the 18 - 24 h incubation period, 25 µL of each exposed cell solution was transferred 
to a 96-well plate and 75 µL of minimal media was added to each well. The OD660 of each well 
was taken with a Molecular Devices Max 3 spectrophotometer plate reader (Sunnydale, CA, 
USA) to determine cell density. β-galactose and Yeast Protein Extraction Reagent (YPER) from 
a ThermoFisher Yeast β-galactosidase assay kit were diluted 1:1 and 100 µL was added to each 
well. The plate was then immediately read every 15 s for 30 min at 420 nm. The β-galactosidase 
activity of each well was reported in E2 equivalents (E2eq). 
2.5.4 Nutrient Analysis 
Analysis for nitrite, nitrate, total nitrogen, chloride, and conductivity was performed by 
Maxxam Analytics (Mississauga, ON) as outlined in Table 2.5.3.  
Table 2.5.3 Nutrient analysis methods and MDLs from Maxxam Analytics (Mississauga, ON) 
Parameter Analysis  MDL 
Ammonia Colourimetry 0.05 mg/L 
Nitrate Determined by subtraction of nitrite value from 
total oxidized nitrogen value 
0.5 mg/L 
Nitrite Colourimetry 0.01 mg/L 
Total oxidized 
nitrogen 
Cadmium column reduction 0.5 mg/L 
Chloride Colourimetry 4 mg/L 
Conductivity Conductivity meter 1.0 umho/cm 
MDL = Method Detection Limit 
2.6 Detection Limits and Quantitation  
2.6.1 Quantitation of LC-MS/MS samples 
Each LC-MS/MS method was optimized to achieve the best possible detection for the 
selected analytes. The chromatographic conditions were optimized for the best separation and 
ionization into the mass spectrometer.  
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Data analysis for the PPCP method was completed with Analyst software version 1.6.1 
(Applied Biosystems). For the estrogen method Agilent MassHunter Quantitative Analysis 
version B.05.02 was used for quantitation. A series of calibration standards at concentrations of 
0, 0.5, 1, 10, 50, 100, 200, and 500 µg/L were run prior to each batch of samples. An additional 
two calibration points at 0.1 and 5 µg/L were added to this for the estrogen analysis. Samples 
were quantified based on the ratio of analyte peak area to isotopically labelled standard peak 
area.  
The instrument detection (IDL) and quantification limits (IQL) were determined by 
running a series of blanks (n=7) as well as a calibration curve with concentrations of 0, 0.1, 0.5, 
1.0, 10, 50, 100, 200, and 500 µg/L. The IDLs were reported as three times the standard 
deviation of the blanks. The IQLs were calculated based on ten times the standard deviation of 
the blanks. 
The method detection limit (MDL) was determined by running a series of wastewater 
samples that had been spiked with various concentrations of standards (0, 5, 10, and 50 ng/L). 
MDLs were calculated at a 99% confidence using a student’s t-test value (n-1) multiplied by the 
standard deviation of 7 samples. The instrument detection and quantification limits as well as the 
method detection limit for each analyte are listed in Table 2.6.1.
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Table 2.6.1. LC-MS/MS method detection limits (MDL) for CECs in wastewater effluents. 
Analyte Surface water MDL 
(ng/L) 
Wastewater MDL (ng/L) 
Triclosan 11.2 56a 
Triclocarban 9.6 48a 
Sulfamethoxazole 1.2 6
a 
Trimethoprim 1.2 6
a 
Carbamazepine 1.54 10.8 
17α-ethynylestradiol  1 3.2 
17β-estradiol 0.5 3 
Estrone 1 4 
Estriol  1 3.6 
Gemfibrozil 3.3 16.5a 
Diclofenac 7.3 36.5a 
Ibuprofen 2.2 21.4 
Naproxen 2.6 16.4 
Fluoxetine 10.33 51.7a 
Venlafaxine 1.36 8.2 
Atorvastatin 8.2 41a 
p-hydroxy Atorvastatin 8.2 41a 
o-hydroxy Atorvastatin 8.2 41a 
aWastewater MDL was calculated as 5x surface water MDL 
2.6.2 YES Assay 
The YES assay was previously validated in the Servos lab for use on wastewater effluent 
samples from the Kitchener and Waterloo WWTPs (Tanna et al. 2013). On each plate, a 
calibration curve of 17β-estradiol standards at concentrations of 1.25E-08, 6.25E-09, 3.13E-09, 
1.56E-09, 7.81E-10, 3.91E-10, 1.95E-10, 9.77E-11, 4.88E-11, 2.44E-11, 1.22E-11 M was run in 
duplicate. QA/QC samples were also run in duplicate on each plate in the form of one positive 
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control (cells and a calibration curve standard), one negative control (MeOH and cells), and a 
blank (cells only).  
The β-galactosidase activity of each well was determined by comparing the rate of 
chromogen production at OD420 by the samples relative to the 17β-estradiol calibration curve 
standards. Readings were taken every 30 s over a 30 m period. Standards or samples that were 
cytotoxic were not considered in calculations. The OD660 of each well was used to correct for the 
volume of cells present. As indicated by the ThermoFisher yeast β-galactosidase assay kit, only 
values between 0.2 and 1 were included in these calculations. The equation used to determine β-
galactosidase activity is as follows, where t = time in minutes of incubation and V = volume of 
cells in mL used in the assay (Equation 1).  
β − galactosidase activity =
1000 × ∆OD420 
𝑡 ×𝑉 × OD660
    Equation 1 
 
Once β − galactosidase activity was determined, the final E2eq of each well in ng/L was 
calculated with the following equation (Equation 2): 
 
𝐹𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐 (
𝑛𝑔
𝐿
𝐸2 𝑒𝑞𝑢𝑖𝑣𝑎𝑙𝑒𝑛𝑡𝑠) =
=
𝐶𝑜𝑛𝑐.  𝑜𝑓 𝐸2 (
𝑚𝑜𝑙
𝐿 ) × 𝑉𝑜𝑙 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑤𝑒𝑙𝑙 (𝜇𝐿)
𝑉𝑜𝑙 𝑜𝑓 𝑒𝑥𝑡𝑟𝑎𝑐𝑡 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙𝑠 𝑎𝑟𝑒 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑡𝑜 (𝜇𝑙)
× 𝑀𝑊 𝑜𝑓 𝐸2 (
𝑔
𝑚𝑜𝑙
)
×
𝑓𝑖𝑛𝑎𝑙 𝑟𝑒𝑐𝑜𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 𝑎𝑓𝑡𝑒𝑟 𝑑𝑟𝑦𝑖𝑛𝑔(𝑚𝐿) 
𝑣𝑜𝑙 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 (𝑚𝐿)
× 𝑠𝑒𝑟𝑖𝑎𝑙 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
Equation 2 
2.7 Statistics 
Most statistical analysis was done in Sigma-Plot v. 13 (Systat Software, San Jose, CA). 
Dose-response curves for the YES assay were calculated with a four-parameter Hill equation. All 
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error bars represent standard deviation as sample sizes were not equal. One-way ANOVAs were 
performed on pharmaceutical and estrogenicity data after it had been log-transformed to ensure 
normality (Shapiro-Wilk test) and equal variances (Brown-Forsythe test) and followed by Tukey 
post-hoc tests. Primer-E v. 7 (Auckland, NZ) was used to perform PCAs on each WWTP.  
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Chapter 3 – Results 
3.1 Nitrate and Ammonia in the Kitchener WWTP effluents 
Ammonia and nitrate concentrations determined from grab samples at the Kitchener 
WWTP aligned with the monitoring data released by the Region of Waterloo (Appendix A4). 
Ammonia concentrations (Figure 3.1.1) were significantly higher (p < 0.001) in the Kitchener 
WWTP in 2010 and 2011 (24.5 ± 6.6 mg/L) than in 2012 (10.7 ± 1.3 mg/L), 2013 (2.1 ± 0.9 
mg/L), 2014 (4.7 ± 5.9 mg/L), and 2015 (2.5 ± 1.9 mg/L). Ammonia levels were consistently 
low from March – December 2013, becoming less consistent in 2014 and 2015, with sudden 
increases occurring in the early spring months (March – May). Nitrate concentrations (Figure 
3.1.1) were significantly lower (p < 0.001) before the upgrades in 2010 and 2011 (1.6 ± 1.6 
mg/L) than during upgrade implementation in 2012 (18.0 ± 3.8 mg/L) or after in 2013 (19.4 ± 
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2.8 mg/L), 2014 (16.2 ± 5.3 mg/L), and 2015 (18.8 ± 3.7 mg/L). From 2013 – 2015, nitrate 
levels were lowest in spring 2014 and spring 2015.  
Figure 3.1.1. Ammonia and nitrate concentrations in the Kitchener WWTP November 
2010 - November 2015. Sampling events corresponded with when samples were taken for CEC 
analysis. 
3.2 Select Pharmaceuticals in the Kitchener WWTP 
The two pharmaceuticals (ibuprofen, naproxen) that were previously identified as 
having high biotransformation potential and low sorption potential were readily removed by the 
WWTP after upgrades were implemented. The concentration of ibuprofen in the Kitchener 
WWTP (Figure 3.2.1) was significantly lower (p < 0.001) in 2013 (26.3 ± 29.6 ng/L), 2014 
(75.3 ± 42.4 ng/L), and 2015 (111 ± 77.7 ng/L) compared to pre-upgrade conditions (3540 ± 
2790 ng/L), though the increase in concentration after 2013 was also significant (p < 0.001). 
Similarly, the concentration of naproxen (Figure 3.2.1) in the Kitchener WWTP effluent was 
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significantly higher (p = 0.005) before upgrades (507 ± 353 ng/L) than during (163 ± 144 ng/L) 
or after in 2013 (25.5 ± 18.9 ng/L), 2014 (56.0 ± 33.9 ng/L), and 2015 (71.8 ± 53.1 ng/L). 
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Figure 3.2.1. Select pharmaceuticals with high biotransformation and low sorption rates in the 
Kitchener WWTP effluents November 2010 - November 2015. Concentrations of ibuprofen and 
Naproxen were reduced significantly (p < 0.001) after the implementation of upgrades in 2012. 
 
In contrast, the two pharmaceuticals previously identified as having low sorption 
potential and low biotransformation potential (carbamazepine, diclofenac) were largely 
recalcitrant in the effluents even after upgrades. The concentration of carbamazepine (Figure 
3.2.2) was significantly reduced (p < 0.001) only in 2013 (236 ± 46.3 ng/L) when compared to 
before upgrades occurred (619 ± 121 ng/L), and was not significantly different in 2014 (434 ± 
221 ng/L) or 2015 (603 ± 313 ng/L). The concentration of diclofenac (Figure 3.2.2) in the 
WWTP effluent was not significantly different from 2010 (413 ± 285 ng/L) to 2015 (830 ± 401 
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ng/L) except for the period in 2012 while upgrades were being implemented (193 ± 278 ng/L), 
when concentrations were significantly lower (p < 0.001). 
Figure 3.2.2. Select pharmaceuticals with low biotransformation and sorption rates in the 
Kitchener WWTP effluents November 2010 - November 2015. Concentrations of carbamazepine 
and diclofenac did not change significantly after the implementation of upgrades in 2012. 
 
The four pharmaceuticals previously identified as having moderate biotransformation 
potential and low sorption potential (sulfamethoxazole, trimethoprim, gemfibrozil, venlafaxine) 
varied in their response to the WWTP upgrades. The concentration of venlafaxine (Figure 3.2.3) 
decreased significantly in the effluent (p < 0.001) in 2013 (911  150 ng/L) and 2014 (953 ± 227 
ng/L) but not in 2015 (1149 ± 309.1 ng/L) compared to before upgrades were implemented 
(1631 ± 231.5 ng/L). Sulfamethoxazole concentrations (Figure 3.2.3) were reduced in Kitchener 
WWTP effluents (p = 0.03) only in 2014. Concentrations of trimethoprim and gemfibrozil 
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(Figure 3.2.3) in the effluent were not significantly different (p > 0.05) across the years from 
2010 – 2015.
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Figure 3.2.3. Select pharmaceuticals with moderate removal through biotransformation and low sorption at the Kitchener 
WWTP 2010 - 2015. The concentrations of sulfamethoxazole, trimethoprim, gemfibrozil, and venlafaxine were variable over time. 
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The concentration of triclosan in the Kitchener WWTP effluents (Figure 3.2.4) was 
significantly lower (p < 0.001) in 2013 (206 ± 86.9 ng/L), 2014 (319 ± 227 ng/L), and 2015 (226 
± 137 ng/L) compared to before-upgrade conditions (818 ± 164 ng/L). The concentration of 
fluoxetine was significantly lower (p = 0.035) than before upgrades (60.6 ± 46.6 ng/L) in 2013 
(14.8 ± 5.24 ng/L) and 2014 (19.6 ± 10.8 ng/L), but not in 2015 (22.9 ± 7.71 ng/L). 
Figure 3.2.4. Select pharmaceuticals with high biotransformation and sorption rates in the 
Kitchener WWTP effluents 2010 - 2015. The concentrations of triclosan and fluoxetine were 
significantly reduced (p < 0.035) in 2013 and 2014; triclosan was also significantly reduced in 
2015 (p < 0.001).
 
The concentration of atorvastatin and its metabolite p-hydroxy atorvastatin in the 
Kitchener WWTP effluents (Figure 3.2.5) were significantly reduced (p < 0.001) only while 
upgrades were being implemented (Sept 2012 – Feb 2013) compared to before-upgrade 
conditions. Levels of atorvastatin and p-hydroxy atorvastatin were also significantly higher (p < 
0.001) in 2013, 2014, and 2015 than in 2012.
Date
N
o
v-
2
0
1
0
M
a
y
-1
1
N
o
v-
1
1
J
u
ly
-2
0
1
2
S
e
p
t-
2
0
1
2
O
c
t-
2
0
1
2
N
o
v-
2
0
1
2
J
a
n
-2
0
1
3
F
e
b
-2
0
1
3
M
a
r-
2
0
1
3
A
p
ri
l-
2
0
1
3
M
a
y
-2
0
1
3
J
u
n
e
-2
0
1
3
J
u
ly
-2
0
1
3
S
e
p
t-
2
0
1
3
D
e
c
-2
0
1
3
M
a
rc
h
-2
0
1
4
M
a
y
-2
0
1
4
J
u
n
e
-2
0
1
4
S
e
p
t-
2
0
1
4
O
c
t-
2
0
1
4
N
o
v-
2
0
1
4
D
e
c
-2
0
1
4
J
a
n
-2
0
1
5
F
e
b
-2
0
1
5
M
a
rc
h
-2
0
1
5
A
p
ri
l-
2
0
1
5
M
a
y
-2
0
1
5
J
u
n
e
-2
0
1
5
J
u
ly
-2
0
1
5
A
u
g
-2
0
1
5
S
e
p
t-
2
0
1
5
N
o
v-
2
0
1
5
C
o
n
c
e
tr
a
ti
o
n
 (
n
g
/L
)
0
200
400
600
800
1000
1200
Triclosan
Fluoxetine
44 
 
 
Figure 3.2.5. Select pharmaceuticals with moderate biotransformation and sorption potential in 
the Kitchener WWTP, 2010 – 2015. Atorvastatin and its metabolite p-hydroxy atorvastatin were 
significantly reduced (p < 0.001) only during the period of upgrade implementation. 
 
The concentration of triclocarban in the Kitchener WWTP effluents (Figure 3.2.6) was 
significantly reduced (p < 0.035) in 2014 (31.5  20.8 ng/L) and (p < 0.001) 2015 (17.3  6.44 
ng/L) compared to before-upgrade conditions (64.7  17.7 ng/L).  
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Figure 3.2.6. Select pharmaceuticals with low biotransformation and high sorption rates, 2010 – 
2015. Triclocarban was significantly reduced (p < 0.035) in 2014 and 2015 compared to pre-
2012 conditions. 
 
Linear regressions were used to model the relationship between each pharmaceutical and 
ammonia or nitrate concentrations in the WWTP effluent (n=33 for all tests). Moderate 
relationships existed between nitrate and triclosan (r2 = 0.61, p < 0.001), ibuprofen (r2 = 0.50, p < 
0.001), and naproxen (r2 = 0.49, p < 0.001). Moderate inverse relationships exist between 
ammonia concentrations and concentrations of ibuprofen (r2 = 0.68, p < 0.001), naproxen (r2 = 
0.62, p < 0.001), and triclosan (r2 = 0.73, p < 0.001) in effluents. Full linear regression results can 
be found in Appendix A3. 
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3.3 Total estrogenicity in the Kitchener WWTP effluents 
The estrogenicity of the Kitchener WWTP effluent (Figure 3.3.1) was significantly 
higher (p < 0.001) in 2010 (22.5 ± 6.52 ng/L E2eq) and 2011 (10.4 ± 1.9 ng/L E2eq) than during 
and after upgrades in Fall 2012 (2.4 ± 1.6 ng/L E2eq), 2013 (0.88 ± 0.53 ng/L E2eq), 2014 (2.0 ± 
0.22 ng/L E2eq), and 2015 (1.5 ± 0.77 ng/L E2eq). Effluent estrogenicity was not significantly 
different from 2012 – 2015. One effluent sample (February 2010, 22.9 ng/L E2eq) was excluded 
from this analysis as it was the only sample that was not collected during autumn (September – 
December). Linear regression analysis showed that total estrogenicity had a relationship with 
both ammonia (r2=0.79, p < 0.01) and nitrate (r2=0.88, p < 0.005). 
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Figure 3.3.1. Estrogenicity in E2 equivalents in the Kitchener WWTP, Fall 2010 - 2015. Total 
estrogenicity was reduced (p < 0.001) in 2012 – 2014 compared to pre-2012 conditions. 
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3.4 Principle components analysis of the Kitchener WWTP effluents, 2010 – 2015 
A principle components analysis (PCA) (Figure 3.4.1) was performed with the 
pharmaceutical and nutrient data in the Kitchener WWTP. Principle component 1 (PC1) 
explained 41.2% of the variability and was primarily driven by total ammonia, followed by 
triclosan, ibuprofen, naproxen, and nitrate in approximately equal quantities. PC2 explained an 
additional 15.3% of the variability and was primarily driven by diclofenac, carbamazepine, and 
nitrate.  Additional information can be found in Appendix A5: Principle components analysis 
details.
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Figure 3.4.1. Principle components analysis for the Kitchener WWTP, 2010 - 2015. 
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3.5 Nitrate and Ammonia in the Waterloo WWTP 
A high level of ammonia (9 – 37 mg/L) with substantial variability was observed in the 
Waterloo WWTP (Figure 3.5.1) from 2011 – 2015. Ammonia levels did not change significantly 
over this time period, though nitrate levels (Figure 3.5.1) were significantly higher (p = 0.015) in 
2015 (9.69  3.52 mg/L) than in pre-2014 (2.36  3.16 mg/L). 
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Figure 3.5.1. Ammonia and nitrate concentrations in the Waterloo WWTP 2011 – 2015. 
Sampling events correspond with sample collections for CEC analysis. 
3.6 Select Pharmaceuticals in the Waterloo WWTP 
Effluent concentrations of ibuprofen (Figure 3.6.1) were significantly lower (p < 0.03) in 
2014 (332  398 ng/L) and 2015 (531  485 ng/L) compared to pre-2014 conditions (1729  
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1744 ng/L). Effluent concentrations of naproxen (Figure 3.6.1) were also significantly lower (p = 
0.025) in 2014 (467  253 ng/L) and 2015 (816  595 ng/L) compared to pre-2014 conditions 
(1850  940 ng/L).  
Date
M
a
y
-1
0
M
a
y
-1
1
N
o
v-
1
1
Ju
ly
-1
2
D
e
c
-1
3
M
a
rc
h
-1
4
M
a
y
-1
4
Ju
ly
-1
4
A
u
g
-1
4
S
e
p
t-
1
4
O
c
t-
1
4
N
o
v-
1
4
D
e
c
-1
4
Ja
n
-1
5
M
a
rc
h
-1
5
A
p
ri
l-
1
5
M
a
y
-1
5
Ju
n
e
-1
5
Ju
ly
-1
5
A
u
g
-1
5
S
e
p
t-
1
5
N
o
v-
1
5
C
o
n
c
e
n
tr
a
ti
o
n
 (
n
g
/L
)
0
1000
2000
3000
4000
5000
6000
Ibuprofen
Naproxen
 
Figure 3.6.1. Select pharmaceuticals with high biotransformation and low sorption rates in the 
Waterloo WWTP effluents, 2010 – 2015. Ibuprofen and naproxen were significantly reduced (p 
< 0.03) after mid-2014. 
 
 Carbamazepine levels (Figure 3.6.2) were significantly higher (p < 0.028) in the 
Waterloo WWTP effluents in 2015 (448  278 ng/L) than in 2014 (181  91.3 ng/L), though 
neither 2014 nor 2015 were significantly different than pre-2014 (341  106 ng/L). Similarly, 
diclofenac levels (Figure 3.6.2) were significantly higher (p < 0.04) in 2015 (552  153 ng/L) 
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than in 2014 (315  191 ng/L), though neither was significantly different from pre-2014 
conditions (307  235 ng/L). 
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Figure 3.6.2. Select pharmaceuticals with low biotransformation and sorption rates in the 
Waterloo WWTP, 2010 - 2015. Carbamazepine and diclofenac did not change significantly in 
response to treatment plant upgrades. 
 
Sulfamethoxazole, trimethoprim, gemfibrozil, and venlafaxine showed the highest 
variability of any group. Gemfibrozil concentrations decreased significantly (p = 0.003) in the 
effluent in 2015 (55.1 ± 17.3 ng/L) compared to both pre-2014 (99.5 ± 7.14 ng/L) as well as 
2014 conditions (81.8  14.0 ng/L). The concentration of sulfamethoxazole decreased 
significantly in the effluent (p < 0.001) in 2014 (186  124 ng/L) and 2015 (173 ± 135 ng/L) 
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compared to pre-2014 conditions (524 ± 106 ng/L). Trimethoprim concentrations were reduced 
in effluents (p < 0.04) only in 2014. Venlafaxine was not significantly changed in the effluent (p 
> 0.05) over the years from 2010 – 2015. 
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Figure 3.6.3. Select pharmaceuticals with moderate removal through biotransformation and sorption in the Waterloo WWTP, 2010 – 
2015. Sulfamethoxazole, trimethoprim, gemfibrozil, and venlafaxine were variable in effluents between 2010 and 2015.
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Triclosan (Figure 3.6.4) was significantly lower (p = 0.02) in 2014 (735 ± 260 ng/L) and 
2015 (p < 0.001) (491 ± 219 ng/L) compared to pre-2014 conditions (1150 ± 267.3 ng/L). 
Similarly, fluoxetine was significantly lower (p < 0.009) in 2014 (7.14 ± 5.49 ng/L) and 2015 (p 
= 0.03) (10.2 ± 6.91 ng/L) compared to pre-2014 (22.3 ± 12.3 ng/L).  
Figure 3.6.4. Select pharmaceuticals with high biotransformation and sorption rates in the 
Waterloo WWTP effluents 2010 - 2015. Triclosan and fluoxetine were reduced in effluents in 
2014 and 2015 compared to pre-2014 conditions.  
 
Atorvastatin was significantly reduced (p < 0.001) in Waterloo WWTP effluents in 2014 
(113 ± 80.0 ng/L) and 2015 (156 ± 27.6 ng/L) compared to pre-2014 conditions (297 ± 84.9 
ng/L). The metabolite p-hydroxy atorvastatin was likewise reduced (p < 0.001) in 2014 (113 ± 
89.6 ng/L) and 2015 (271 ± 65.3 ng/L) compared to pre-2014 (336 ± 18.2 ng/L). 
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Figure 3.6.5. Select pharmaceuticals with moderate biotransformation and sorption rates in the 
Waterloo WWTP effluents, 2010 - 2015. Atorvastatin and p-hydroxy atorvastatin were reduced 
in effluents in 2014 and 2015 compared to pre-2014 conditions. 
 
Linear regression analyses were performed to model the relationship between each 
pharmaceutical and ammonia or nitrate concentrations in the WWTP effluent (n=21 for all tests). 
When the relationships between nitrate and select CECs were modeled, the strongest present 
were with nitrate and sulfamethoxazole (r2 = 0.43, p = 0.001) and venlafaxine (r2= 0.40, p = 
0.002). When the relationships between ammonia and select CECs were considered, the 
strongest present were between ammonia and triclocarban (r2=0.50, p < 0.001), ibuprofen 
(r2=0.34, p < 0.001), and naproxen (r2=0.36, p < 0.001). Full linear regression results can be 
found in Appendix A3. 
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3.7 Total estrogenicity in the Waterloo WWTP 
The estrogenicity of the Waterloo WWTP effluent (Figure 3.7.1) was highly variable over 
the years 2009 – 2015. Fall 2014 had the lowest estrogenicity (2.3  0.60 ng/L E2eq), and was 
significantly lower (p < 0.001) than any other year. Similarly, Fall 2011 (5.3  0.90 ng/L E2eq) 
was significantly lower (p < 0.001) than every other year except for Fall 2015 (10.8  2.89 ng/L 
E2eq). When grouped similarly to the pharmaceutical data, pre-2014 (13.8  1.89 ng/L E2eq) is 
significantly higher (p < 0.001) than 2014, but not 2015. 
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Figure 3.7.1. Total estrogenicity in E2 equivalents at the Waterloo WWTP, 2009 - 2015. The 
total estrogenicity of the Waterloo WWTP effluent was highly variable over time. 
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3.8 Principle Components Analysis of the Waterloo WWTP, 2010 – 2015 
A principle components analysis was performed with the pharmaceutical and nutrient 
data in the Kitchener WWTP. PC1 explained 31.2% of the variability and was primarily driven 
by ibuprofen, naproxen, and venlafaxine. PC2 explained an additional 20.0% of the variability 
and was primarily driven by nitrate, sulfamethoxazole, and fluoxetine. Additional information 
can be found in Appendix A5: Principle components analysis details.  
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Figure 3.8.1. Principle Components Analysis of the Waterloo WWTP, 2011 - 2015. 
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3.9 Select estrogens in the Kitchener and Waterloo WWTP effluents 
The method developed to measure select estrogens in WWTP effluents worked well with 
low detection limits ( < 1 ng/L) in clean water, and passed all necessary validation requirements 
(specificity, selectivity, reproducibility, etc.). However, when this method was applied to 
effluents from the Kitchener and Waterloo WWTPs, matrix effects resulted in data that was 
suspect and requires additional analysis on a more mass selective instrument (accurate rather 
than nominal mass resolution) before it can be published. 
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Chapter 4 – Discussion 
The presence of CECs in wastewater effluents during major upgrades to the treatment 
process was investigated at two treatment plants in the Grand River watershed. The results 
provide evidence that upgrades to wastewater treatment (resulting in longer SRTs and 
nitrification) will decrease the concentrations of key pharmaceuticals and estrogenicity in 
wastewater effluents. Specifically, this work demonstrates that the impact of upgrades to 
wastewater treatment plants on CEC removal is compound-dependent, and is influenced by the 
physiochemical properties of each CEC and the specific treatment process within each plant. It is 
important to note that CECs are reported here as concentrations rather than as loads due to the 
relevance of concentration when estimating potential exposure. Flow rates for both the Kitchener 
and Waterloo WTTPs are provided in Appendix A6: Flow Data for the Kitchener and Waterloo 
WWTPs. 
4.1 Nutrients in the Kitchener WWTP before and after upgrades 
The upgrades to the Kitchener WWTP in late 2012 and early 2013, including improved 
aeration and secondary treatment train reconfiguration, were implemented to increase the SRT 
(from <2 days to 5.4 days) and introduce more diverse and slow-growing bacterial communities 
to the secondary treatment process (Bicudo et al. 2016). The resulting nitrification is reflected in 
a significant decrease in ammonia levels and increase in nitrate levels in effluents from the plant 
after upgrades were implemented. The changes in ammonia and nitrate were reflected both in 
grab samples taken at each CEC sampling event and in the biweekly monitoring data from the 
Region of Waterloo (Figure 3.1.1, Figure A4.1). This is consistent with expectations as well as 
typical outcomes associated with improved aeration in CAS systems (Bicudo et al. 2016). 
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Increased nitrification is typically associated with higher quality treatment, and nitrifying plants 
have been shown to improve removal of a number of CECs and reduce effluent estrogenicity 
(Servos et al. 2005; Suarez et al. 2010; Fernandez-Fontaina et al. 2012).  
4.2 Pharmaceuticals in the Kitchener WWTP before and after upgrades 
A suite of key CECs was investigated to determine the impact of WWTP upgrades on a 
number of pharmaceuticals with varying physiochemical properties (Table 1.8.1). CECs were 
categorized based on their expected removal through biotransformation and sorption, the two 
main mechanisms by which CECs are removed in WWTPs (Salveson et al. 2012).  
CECs that were classified as readily biotransformed in this system with low sorption 
potential (ibuprofen, naproxen) showed a significant decrease in the effluents of the Kitchener 
WWTP after major upgrades to the treatment process, including nitrification. This is consistent 
with literature that shows ibuprofen, naproxen, and other compounds with similar 
physiochemical properties are readily removed from CAS systems with nitrifying treatment and 
an SRT of over 5 days (Clara et al. 2005; Joss et al. 2005; Salveson et al. 2012). These 
compounds are both small molecules with structural segments that are amenable to biological 
attack (i.e. an aliphatic region) and low sorption potential, and are therefore excellent candidates 
for rapid biotransformation (Salveson et al. 2012).  
Biotransformation is also integral in the removal of triclosan and fluoxetine from this 
system. These compounds were used to determine the behavior of CECs classified as having 
high biotransformation and sorption potential. The concentrations of both triclosan and 
fluoxetine were significantly reduced in Kitchener WWTP effluents in 2013 and 2014, though 
the concentration of fluoxetine was not significantly different in 2015 compared to before 
upgrade conditions. Results from other studies demonstrate that readily biodegradable CECs, 
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including fluoxetine, show improved removal in nitrifying conditions (Fernandez-Fontaina et al. 
2012), and that triclosan is readily biodegraded by ammonia oxidizing bacteria (Roh et al. 2009). 
Though there is no clear consensus on whether longer SRTs improve removal of highly sorbable 
CECs, there is indication that sludge age could influence removal of CECs by sorption due to 
changes in the biomass (percent active fraction, specific microbial population) (Clara et al. 2005; 
Joss et al. 2005; Joss et al. 2006; Hyland et al. 2012).  
 Unlike CECs with high biotransformation rates, those with moderate biotransformation 
rates showed high variability in removal success between compounds within the same group. 
Those with moderate biotransformation and low sorption potential were responsible for this 
variability. While venlafaxine was significantly decreased in effluents in 2013 and 2014, 
sulfamethoxazole was only reduced in 2014, and trimethoprim and gemfibrozil showed no 
significant reduction over the years 2010 – 2015. Previous work shows CECs within this group 
may be removed from 0 – 100% in CAS conditions, varying substantially based on the specific 
compound being investigated and the operating parameters of the WWTP (Salveson et al. 2012). 
A more accurate estimate of removal for a particular compound within this group may be 
achieved by considering the SRT of the WWTP in question (Clara et al. 2005; Salveson et al. 
2012). Atorvastatin and p-hydroxy atorvastatin, which represented the moderate sorption and 
moderate biotransformation group, were only significantly reduced during the period where 
upgrades were coming online (Sept 2012 – Feb 2013), but not afterwards (March 2013 – 
November 2015). 
CECs that were classified as having low biotransformation rates and low sorption rates 
were highly recalcitrant in effluents even after upgrades occurred, with diclofenac significantly 
reduced only while upgrades were being implemented and carbamazepine significantly reduced 
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only in 2013. Numerous studies have shown that both of these compounds are difficult to remove 
from wastewater even with advanced treatment in nitrifying systems with long SRTs (Zhang et 
al. 2008; Fernandez-Fontaina et al. 2012; Vieno & Sillanpaa 2014). Finally, the one CEC that 
typically shows low biotransformation and sorption rates (triclocarban) was significantly reduced 
in effluents after the implementation of upgrades.  
Overall, CECs that had high biotransformation potential were most significantly 
impacted by the upgrades implemented at the Kitchener WWTP, with all CECs in this category 
showing significant decline after their implementation. Moderately biotransformed CECs were 
highly variable, with some showing significant reduction after upgrades and others remaining 
recalcitrant in effluents. CECs that are slowly biotransformed and not readily amenable to 
biological attack remained recalcitrant in effluents. The Kitchener WWTP experienced an upset 
in early 2014 that resulted in a spike in ammonia and a reduction in nitrate in the effluents. This 
upset was reflected in some of the readily biotransformed CECs that have an inverse relationship 
with ammonia concentration, particularly triclosan. Based on the PCA, the three time periods 
(before, during, and after upgrades) are clearly separated from one another when all CECs and 
nitrate/ammonia concentrations in effluent are taken into account, and the upset months (March 
2014, May 2014) are also distinct from the majority of post-upgrade samples. 
4.3 Total estrogenicity of the Kitchener WWTP effluent 
The total estrogenicity of the effluent as measured by the YES assay was significantly 
reduced after the implementation of upgrades. Williams et al. (2009) modeled the risk of 
endocrine disruption in over 10,000 reaches impacted by estrogenic WWTP effluents using the 
PNECs of E1, E2, and EE2 as well as their relative potency. Their parameters for low, moderate, 
and high risk were < 1.0 ng/L E2eq, > 1.0 ng/L E2eq, and > 10.0 ng/L E2eq respectively in 
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impacted surface waters. Following this model, direct exposure to the levels of estrogenicity in 
the Kitchener WWTP effluents would put populations at high risk before upgrades were 
implemented (12.3 ± 4.14 ng/L E2eq), no risk in 2013 (0.57 ± 0.08 ng/L E2eq), and moderate 
risk in 2014 (1.7 ± 0.48 ng/L E2eq) and 2015 (2.1 ± 0.21 ng/L E2eq). It is important to note that 
the dilution that occurs when effluent enters the receiving environment will reduce these 
concentrations in surface water. The increase in 2014 and 2015 may be due to issues with the 
operation of the new aerators as well disruption of operations due to ongoing construction at the 
WWTP (Bicudo et al. 2016). The reduction in the estrogenicity of the WWTP effluents in 
association with upgrades to nitrifying treatment is consistent with literature, which demonstrates 
reduced estrogenicity in the effluents of nitrifying plants (Servos et al. 2005; Luo et al. 2014). As 
estrone and 17β-estradiol were two of the main species responsible for the estrogenicity of the 
Kitchener WWTP effluents (Smith 2013), it is also consistent with other readily 
biotransformable CECs in the Kitchener WWTP, all of which showed significant reduction after 
upgrades with the lowest levels occurring in 2013. Of all the CECs that showed significant 
reduction when upgrades were implemented, total estrogenicity had the closest relationship with 
both total ammonia and nitrate concentrations in the effluents. 
4.4 Nutrients in the Waterloo WWTP from 2010 - 2015 
 The Waterloo WWTP performed inconsistently from 2010-2015. Ammonia levels 
remained high within the plant over this time period, though nitrate levels did increase 
significantly in 2015 compared to pre-2014 conditions. Typically, if an increase in nitrate is as a 
result of nitrifying treatment, it would be associated with a decrease in ammonia. In the Waterloo 
WWTP from 2011 - 2015, ammonia remains high even as nitrate increases, with the exception of 
2014 concentrations. This is likely due to the delays in construction and upgrades at the WWTP. 
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Though a return activated sludge (RAS) was implemented, upgrades to aeration were not, 
resulting in high ammonia loads even when partial nitrification is occurring during secondary 
treatment. In 2014, a re-aeration zone was introduced to the RAS system, resulting in a drop in 
ammonia and an increase in nitrate. However, the plant is still operating with mechanical surface 
aeration in the remainder of the secondary treatment train. Improvements to aeration are crucial 
to the reduction of ammonia in WWTP effluents, so the ammonia at this plant will likely remain 
elevated until additional upgrades are implemented.  
4.5 Pharmaceuticals and total estrogenicity in the Waterloo WWTP from 2010 – 2015 
The concentrations of all pharmaceuticals in the Waterloo WWTP were highly variable 
over time, but followed the same general patterns of those at the Kitchener WWTP when process 
changes are considered. Similarly to the Kitchener WWTP, there was a reduction in readily 
biodegradable compounds (ibuprofen, naproxen, triclosan, fluoxetine) in 2014 and 2015 after the 
implementation of a RAS re-aeration zone at the Waterloo WWTP. Their continued presence in 
effluents at higher levels than in the Kitchener WWTP may be due to the incomplete nature of 
upgrades at the Waterloo WWTP, where secondary treatment still employs surface mechanical 
aeration with a relatively short SRT (<5 days). The moderately biotransformed pharmaceuticals 
were once again highly variable, with sulfamethoxazole significantly reduced in 2014 and 2015, 
trimethoprim reduced in 2014 only, gemfibrozil reduced in 2015 only, venlafaxine unchanged 
across the years, and atorvastatin and its metabolite reduced in 2014 and 2015. The recalcitrant 
compounds carbamazepine and diclofenac were unchanged in 2014 and increased in the effluents 
in 2015 compared to pre-2014 conditions. 
Total estrogenicity in the Waterloo WWTP effluents was likewise highly variable. Total 
estrogenicity in 2014 and 2015 was lower when compared to pooled pre-2014 data, but looking 
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at year-to-year comparisons illustrates high variability between years before 2014. Fall 2009, 
2010, and 2013 had high total estrogenicity (above 10 ng/L E2eq), while 2011, 2014, and 2015 
were lower (above 1 ng/L E2eq but below 10 ng/L E2eq). The Waterloo WWTP has 
significantly lower daily flow than the Kitchener WWTP, serving roughly half the number of 
people. This needs to be considered when predicting exposure and effects, such as intersex in 
fish, in the receiving environment. 
4.6 Treatment upgrades and their impacts on CECs 
Since effluents are complex mixtures potentially containing hundreds of different CECs 
and other contaminants, it is not feasible to measure each individual contaminant. To be useful, 
indicator compounds should be present in wastewater effluents and surface waters in measurable 
quantities, relatively straightforward to analyse, and commonly used so they are present on a 
wide scale in WWTPs (Salveson et al. 2012). Ibuprofen, naproxen, and triclosan typically meet 
all of these conditions, and their removal was significantly increased as the plant moved from 
non-nitrifying to partially/fully nitrifying treatment. Total estrogenicity had the strongest 
relationship with ammonia and nitrate levels in the Kitchener WWTP, clearly indicating 
improvements to effluent quality. These compounds, as well as total estrogenicity, may therefore 
be useful as key indicators of high-quality CAS plants employing nitrification in the secondary 
treatment process. In the case of this research, influent concentrations were not measured in the 
WWTP. Though this information would have been beneficial to more accurately determine the 
change in removal over time, historical influent samples were not available. Additionally, the 
quantitation of CECs in influents is difficult due to the extremely complex matrix, and would 
likely require the development of additional extraction and analysis methods. As influent 
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concentrations were not quantitated, the reduction of these key CECs in effluents cannot be 
causatively linked to the changes in treatment process. 
4.7 Conclusions 
The upgrades implemented in the Kitchener WWTP significantly reduced the presence of 
highly biodegradable pharmaceuticals in and total estrogenicity of the effluents, while the 
inconsistent treatment at the Waterloo WWTP is reflected in many of the pharmaceuticals as 
well as total estrogenicity. Key pharmaceuticals with high biodegradation rates (ibuprofen, 
naproxen, triclosan) may be useful as indicators for the quality of and upgrades to the secondary 
treatment process within an associated WWTP. This work has implications for the interpretation 
of biological assessments currently being performed downstream of these major WWTPs in the 
Grand River watershed. These studies are examining the impacts of these two major WWTPs on 
biota living downstream of effluent discharges at multiple levels of biological organization. 
Manuscripts currently in preparation show a decline in intersex in rainbow darter downstream of 
the Kitchener WWTP (Hicks et al., University of Waterloo, personal communication), consistent 
with the YES assay performed on these effluents which shows a significant decline in 
estrogenicity after the implementation of upgrades. A thorough characterization of the effluent 
chemistry is a crucial element in determining the potential exposure of downstream biota for 
studies looking at exposure, impact, or recovery. 
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Appendices 
A1: Additional LC-MS/MS Parameters for analysis of CECs 
 A number of parameters must be optimized for each contaminant analysed with LC-
MS/MS to ensure optimal sensitivity and selectivity.
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Table A1.1. Source parameters for the detection of select analytes on a AB Sciex 3200 Qtrap 
mass spectrometer.  
Analyte  DP EP CEP CE CXP 
Atorvastatin 83 5.9 18.91 32 22 
p-hydroxy atorvastatin 46 7.5 20 25 14 
Carbamazepine 55 4.9 14 51 2.7 
Diclofenac -22.5 -22.5 -15 -15 -1.7 
Fluoxetine 48 2.9 12.08 44 7 
Gemfibrozil -20.9 -20.9 -17 -17 -3 
Ibuprofen -41 -2.6 -19 -11 -0.5 
Naproxen -29 -1.9 -20 -25 -3.8 
Sulfamethoxazole 41 3 9 22.1 3 
Triclocarban -12 -12 -20 -20 -13 
Triclosan -33 -2.0 -7 -30 -3.0 
Trimethoprim 59 4 12 32 3  
Venlafaxine 38 2.9 21 42 8.0  
Surrogate       
Atorvastatin 45.6 4 25.9 30 16  
p-hydroxy atorvastatin 64 4 19 32 5  
Carbamazepine-d10 61 4.3 17 28 3.1  
Diclofenac -22.7 -22.7 -16.9 -16.9 -6.1  
Fluoxetine- d5 50 4 12.9 38.2 3.1  
Gemfibrozil -21.1 -21.1 -19.2 -19.2 -2  
Ibuprofen-d3 -25 -7.6 -19 -10 -3.0  
Naproxen-d3  -15 -5.0 -10 -20 -3.0  
Sulfamethoxazole-d4 36 12 14 21 4  
Triclocarban -23.4 -23.34 -18 -18 -2  
Triclosan-d3  -33 -2.0 -7 -30 -3.0  
Trimethoprim-d3 46 8.5 22 31 6  
Venlafaxine-d6 45 3.3 18 45 2.4  
DP=declustering potential; EP=entrance potential; CEP=collision cell entrance potential; CE=collision energy; 
CXP=collision exit potential. 
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Table A1.2 Analysis parameters for select Estrogens on the QQQ 
Analyte Q1 Q3 Polarity 
Ret Time 
(min) Fragmentor 
Collision 
Energy 
Cell Accelerator 
Voltage 
Bisphenol A 227.3 133.2 Negative 7.86 128 26 4 
  212.3 Negative 7.86 128 14 4 
Estrone 269.4 145.1 Negative 8.3 155 38 4 
  143.1 Negative 8.3 155 45 4 
Estradiol 271.4 145.1 Negative 7.99 200 40 4 
  143.1 Negative 7.99 200 56 4 
Estriol 287.4 171.2 Negative 6.23 170 30 4 
  145.1 Negative 6.23 170 38 4 
Ethinylestradiol 295.39 158.9 Negative 8.37 170 32 4 
  144.9 Negative 8.37 170 38 4 
Triclosan 286.99 35 Negative 10.5 90 10 4 
Surrogates        
Bisphenol A - d16 241.28 223.3 Negative 7.82 140 16 4 
  142.2 Negative 7.82 140 24 4 
Estrone - d2 271.2 147.1 Negative 8.3 170 38 4 
  145.1 Negative 8.3 170 58 4 
Estrone-d4 273.4 147.1 Negative 8.3 187 36 4 
  145.1 Negative 8.3 187 50 4 
Estradiol-d4 275.2 187.2 Negative 7.95 147 42 4 
  145.3 Negative 7.95 147 34 4 
Estriol-d2 289.39 173.2 Negative 6.23 200 33 4 
  147.1 Negative 6.23 200 37 4 
  145.1 Negative 6.23 200 53 4 
Estriol-d3 290.2 173.2 Negative 6.23 147 38 4 
  145.3 Negative 6.23 147 50 4 
Ethinylestradiol - d4 299.4 161.2 Negative 8.37 170 34 4 
  147.2 Negative 8.37 170 38 4 
Triclosan-d3 289.99 35 Negative 10.46 90 9 4 
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A2: Reagents required for the YES Assay 
This appendix provides additional details regarding the preparation and storage of 
reagents required to run the Yeast Estrogen Screen (YES) assay. Reagents for the YES assay 
were prepared no more than three weeks prior to use. All reagent storage bottles were autoclaved 
for 35 minutes on a liquid cycle at 120°C and allowed to cool before use to ensure sterility. A 
laminar flow hood was used when possible to reduce potential contamination. When suction 
filtration necessitated work on an open bench, a Bunsen burner was used to provide a sterile 
work area. All solutions were sterilized with a 0.2 µm suction filter into an autoclaved glass 
screw top bottle. 
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Table A2.1. Reagents and media required for the YES Assay. 
Material Contents Storage 
Agar Plate 10 mL 10X YNB, 2 g Bactoagar, 28 mL MilliQ H2O 4°C, inverted 
GOLD 
Concentrate 
600 mL dd H2O, amino acids (See table 2.8.2) 4°C 
GOLD Media 60 mL 20% dextrose, 60 mL 10x YNB, 110 mL GOLD concentrate, 
370 mL MilliQ H2O 
4°C 
Minimal Media 100 mL 10X YNB, 100 mL 20% dextrose, 10 mL L-lysine, 10 mL L-
histidine, 780 mL MilliQ H2O 
4°C 
20% Dextrose 200 g dextrose, 700 mL MilliQ H2O 4°C 
Copper II Sulfate 250 mg copper II sulfate pentahydrate, 100 mL MilliQ H2O 4°C 
YNB = Yeast Nitrogen Base without amino acids
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Table A2.2. Amino acid stock solutions, storage conditions, and volume used in GOLD concentrate. 
Compound Stock solution (g/L) Storage Volume for GOLD concentrate (mL) 
Adenine Sulfate 1.2 RT 75 
L-Histidine-HCl 2.4 4°C 50 
L-Arginine-HCl 2.4 4°C 25 
L-Methionine 2.4 4°C 25 
L-Tyrosine 0.9 RT 25 
L-Isoleucine 3.6 4°C 25 
L-Lysine-HCl 3.6 4°C 100 
L-Phenylalanine 3.0 RT 25 
L-Glutamic Acid 6.0 RT 25 
L-Aspartic Acid 4.0 RT 25 
L-Valine 18.0 4°C 25 
L-Threonine 24.0 4°C 25 
L-Serine 45.0 4°C 50 
L-Leucine 3.6 RT 25 
L-Tryptophan 4.8 4°C 50 
Uracil 2.4 RT 25 
RT = Room Temperature
80 
 
A3: Linear regression analysis of CECs, Nitrate, and Ammonia 
 Linear regressions were used to model the relationship between key CECs and ammonia 
or nitrate in the WWTP effluents. The result of all regressions are listed below for each WWTP 
(Kitchener, Waterloo).
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Table A3.1. Linear regression r2 values and p-values for select pharmaceuticals vs nitrate in the 
Kitchener WWTP, n = 33 for each test. 
Pharmaceutical R2 p-value 
Atorvastatin n/a > 0.05 
p-hydroxy Atorvastatin n/a > 0.05 
Carbamazepine 0.12   0.048 
Diclofenac n/a > 0.05 
Fluoxetine 0.16   0.023 
Gemfibrozil n/a > 0.05 
Ibuprofen 0.50 < 0.001 
Naproxen 0.49 < 0.001 
Sulfamethoxazole n/a > 0.05 
Trimethoprim n/a > 0.05 
Triclocarban n/a > 0.05 
Triclosan 0.61 < 0.001 
Venlafaxine 0.13     0.041 
 
Table A3.2. Linear regression r2 values and p-values for select pharmaceuticals vs total ammonia 
in the Kitchener WWTP, n = 33 for each test. 
Pharmaceutical R2 p-value 
Atorvastatin n/a > 0.05 
p-hydroxy Atorvastatin n/a > 0.05 
Carbamazepine n/a > 0.05 
Diclofenac n/a > 0.05 
Fluoxetine 0.19 < 0.01 
Gemfibrozil 0.24    0.004 
Ibuprofen 0.68 < 0.001 
Naproxen 0.62 < 0.001 
Sulfamethoxazole 0.18    0.013 
Trimethoprim n/a > 0.05 
Triclocarban 0.18    0.012 
Triclosan 0.73 < 0.001 
Venlafaxine 0.13 < 0.001 
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Table A3.3. Linear regression r2 values and p-values for select pharmaceuticals vs nitrate in the 
Waterloo WWTP, n = 21 for each test. 
Pharmaceutical R2 p-value 
Atorvastatin 0.34   0.006 
p-hydroxy Atorvastatin n/a > 0.05 
Carbamazepine n/a > 0.05 
Diclofenac n/a > 0.05 
Fluoxetine n/a > 0.05 
Gemfibrozil 0.31 < 0.001 
Ibuprofen 0.27   0.02 
Naproxen 0.25   0.02 
Sulfamethoxazole 0.43   0.001 
Trimethoprim n/a > 0.05 
Triclocarban n/a > 0.05 
Triclosan 0.21   0.035 
Venlafaxine 0.40   0.002 
 
Table A3.4. Linear regression r2 values and p-values for select pharmaceuticals vs total ammonia 
in the Waterloo WWTP, n = 21 for each test. 
Pharmaceutical R2 p-value 
Atorvastatin n/a > 0.05 
p-hydroxy Atorvastatin n/a > 0.05 
Carbamazepine n/a > 0.05 
Diclofenac n/a > 0.05 
Fluoxetine n/a > 0.05 
Gemfibrozil 0.20   0.04 
Ibuprofen 0.34 < 0.001 
Naproxen 0.36 < 0.001 
Sulfamethoxazole 0.22   0.03 
Trimethoprim n/a > 0.05 
Triclocarban 0.50 < 0.001 
Triclosan 0.22   0.03 
Venlafaxine n/a > 0.05 
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A4: Ammonia and Nitrate data from the Region of Waterloo 
 The data from monthly grab samples taken at the Kitchener and Waterloo WWTP and 
analysed for total ammonia and nitrate concentrations was compared to the average monthly data 
released by the Region of Waterloo (ROW) monitoring programs at both WWTPs. Data (nitrate, 
total ammonia) has been supplied under agreement with the Regional Municipality of Waterloo. 
Sampling data matched well with the ROW for the Kitchener WWTP, both showing a sharp 
decline in ammonia and a corresponding increase in nitrate after 2012. The data for the Waterloo 
WWTP was significantly more variable on a month-to-month basis, so the yearly averages do 
not as closely mirror the data collected on a monthly basis, though the drop in ammonia in 2014 
from pre-2014 conditions and the following increase in ammonia in 2015 is captured in both 
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datasets. 
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Figure A4.1. Annual mean ammonia and nitrate concentrations at the Kitchener WWTP 2007 - 
2015, data provided by the Region of Waterloo. 
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Figure A4.2. Annual mean ammonia and nitrate data for the Waterloo WWTP 2007 – 2015; data 
provided by the Region of Waterloo.
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A5: Principle components analysis details 
 A principle components analysis (PCA) was performed for each of the WWTPs 
(Kitchener and Waterloo). This analysis covered all sampling dates and considered all CECs 
measured as well as total ammonia and nitrate.  
Table A5.1. Principle components analysis details for the Kitchener WWTP, 2010 - 2015. 
Principle 
component 
Eigenvalues %variation Cum. %variation 
1 5.77 41.2 41.2 
2 2.15 15.3 56.6 
3 1.28 9.1 65.7 
4 1.16 8.3 74.0 
5 0.833 5.9 79.9 
6 0.807 5.8 85.7 
7 0.622 4.4 90.1 
8 0.434 3.1 93.2 
9 0.393 2.8 96.0 
10 0.221 1.6 97.6 
 
Table A5.2. Eigenvectors (coefficients in the linear combinations of variables making up 
principle components (PCs)) for the Kitchener WWTP, 2010 – 2015. 
Variable PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
NH4 -0.385 0.147 -0.064 0.113 -0.066 0.063 -0.059 0.222 -0.038 0.226 
NO3 0.309 -0.317 0.161 -0.226 0.029 -0.132 0.247 0.209 0.060 -0.309 
IBU -0.353 0.120 -0.077 0.144 0.344 0.155 0.340 0.121 0.016 -0.210 
NPX -0.350 0.075 -0.225 0.158 0.289 -0.087 0.280 -0.084 0.120 -0.452 
CBZ -0.156 0.435 0.128 -0.332 -0.415 -0.186 0.063 0.143 -0.451 -0.350 
VEN -0.309 -0.152 0.065 -0.408 -0.125 -0.321 -0.093 0.170 0.244 -0.112 
DCF 0.160 0.449 0.286 0.194 -0.143 -0.165 0.413 -0.474 0.016 0.129 
TCS -0.354 0.125 -0.093 0.083 0.032 -0.205 -0.369 -0.026 -0.162 0.282 
TCB -0.175 -0.210 0.556 0.238 -0.002 0.358 -0.363 -0.216 -0.242 -0.401 
SMZ -0.228 -0.008 0.393 -0.416 0.145 0.450 0.348 0.127 -0.022 0.401 
TRI -0.224 -0.317 0.194 -0.196 0.302 -0.490 0.043 -0.480 -0.131 0.145 
FLX -0.226 -0.157 -0.335 -0.244 -0.478 0.349 0.050 -0.511 0.275 -0.088 
GFB -0.218 -0.139 0.378 0.414 -0.396 -0.215 0.126 0.224 0.470 0.068 
Ator 0.084 0.490 0.216 -0.263 0.294 0.035 -0.388 -0.083 0.564 -0.141 
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Table A5.3. Principal component scores by date for the Kitchener WWTP, 2010 – 2015. 
Sample Score 1 Score 2 Score 3 Score 4 Score 5 Score 6 Score 7 Score 8 Score 9 Score 10 
2010November -3.42 0.331 0.452 -0.504 -1.45 1.13 -1.42 -1.27 -0.187 0.59 
2011May -7.99 1.44 1.19 0.306 2.06 0.85 1.25 1.33 0.0112 0.265 
2011November -2.96 2.8 0.951 -0.1 0.645 0.127 -1.25 -0.112 0.587 -0.129 
2012Ju1y -5.84 -0.138 -3.19 0.983 -0.318 0.766 0.771 -0.923 0.119 -1.09 
2012September -1.48 -1.6 0.243 -1.21 0.172 -0.355 -0.639 0.723 -1.48 0.368 
2012October 0.623 0.682 -0.705 0.798 -0.672 -0.109 -0.283 0.687 -0.538 0.133 
2012November -3.16 -2.7 -1.25 -0.0636 1.25 -3.46 -0.28 -1.09 -0.444 0.359 
2013January -1.96 -2.6 -0.548 -2.47 -1.99 1.38 1.01 -0.114 0.578 0.822 
2013February -2.32 -3.7 3.43 0.71 -1.43 -0.464 -0.256 0.674 0.425 -0.963 
2013March 0.909 -0.844 -0.0758 0.65 -0.188 -0.119 0.0023 0.167 0.795 0.455 
2013April 1.51 -1.13 -0.338 0.944 0.124 0.0479 0.38 0.364 0.0481 0.384 
2013May 1.65 -1.03 0.213 0.499 0.308 0.192 0.0488 0.492 0.282 -0.0591 
2013June 1.72 -0.497 0.0754 0.443 0.553 0.35 0.448 -0.181 -0.165 0.585 
2013July 2 -1.06 -0.101 0.0327 0.837 0.87 -0.00382 0.252 -0.695 -0.129 
2013September 1.54 -0.641 -0.245 -0.137 0.714 0.54 -0.0237 -0.0387 -0.724 0.181 
2013December 0.95 0.15 1.1 -0.736 1.48 0.435 -0.41 -0.736 0.281 0.417 
2014March -0.779 2.38 -0.813 1.14 -2.09 -0.97 -1.14 1.27 -0.656 0.258 
2014May 0.874 1.33 0.529 2.91 -0.839 -0.496 1.92 -0.761 0.163 0.635 
2014June 1.6 -0.121 0.858 1.34 -0.0705 -0.41 0.477 0.0979 0.454 0.346 
2014September 1.5 -0.607 -1.68 0.521 0.0214 0.4 -0.0799 0.627 0.194 -0.413 
2014October 2.07 -0.675 -1.59 0.186 -0.159 0.493 -0.148 0.347 0.448 -0.272 
2014November 1.38 0.418 1.49 0.853 0.16 0.419 -0.0416 -1.25 -0.241 -0.197 
2014December 0.963 -0.273 -0.221 -0.738 0.108 -0.442 -0.112 0.351 0.341 -0.307 
2015January 1.09 0.993 0.77 -1.22 -0.00834 -0.981 0.117 -0.365 1.23 -0.495 
2015Februahy 0.831 0.857 0.0387 -0.796 -0.309 -0.949 0.508 0.0688 0.0612 -0.446 
2015March 0.141 1.44 -0.345 -0.612 -0.235 -0.154 -0.886 -0.439 0.978 0.081 
2015April 0.771 0.819 -0.639 -0.249 0.449 -0.244 -0.517 0.528 0.504 -0.151 
2015May 0.0191 1.13 -0.144 0.0877 -0.0483 -0.22 -1.05 0.0251 -0.0161 0.399 
2015June 1.4 -0.574 0.615 1.26 0.509 1.41 -1.04 -0.77 -1.01 -0.703 
2015July 1.48 -0.313 -0.0878 -0.546 0.217 -0.029 0.37 -0.031 -0.262 -0.522 
2015August 1.88 0.32 -0.644 -0.742 0.489 0.953 0.358 0.0118 -0.0966 0.163 
2015September 0.997 2.79 1.03 -2.1 -1.09 -0.71 1.71 -0.381 -1.43 -0.485 
2015November 2 0.631 -0.378 -1.44 0.798 -0.25 0.215 0.44 0.445 -0.0816 
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Table A5.4. Principle components analysis details for the Waterloo WWTP, 2010 - 2015. 
Principle 
component 
Eigenvalues %variation 
explained 
Cum. %variation 
explained 
1 4.37 31.2 31.2 
2 2.79 20.0 51.1 
3 1.58 11.3 62.4 
4 1.29 9.2 71.7 
5 1.16 8.3 80.0 
6 0.742 5.3 85.3 
7 0.644 4.6 89.9 
8 0.518 3.7 93.6 
9 0.328 2.3 95.9 
10 0.235 1.7 97.6 
 
Table A5.5. Eigenvectors (coefficients in the linear combinations of variables making up 
principle components (PCs)) for the Waterloo WWTP, 2011 – 2015. 
Variable PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
NH4 0.288 -0.200 0.341 -0.210 0.037 -0.238 0.041 -0.568 0.295 -0.345 
NO3 -0.261 0.435 -0.185 0.039 -0.051 0.048 -0.041 -0.133 -0.147 -0.237 
IBU 0.419 -0.054 0.053 -0.241 -0.156 0.023 -0.201 0.057 -0.375 -0.245 
NPX 0.434 -0.010 0.078 -0.132 0.031 -0.016 0.085 -0.151 -0.365 0.443 
CBZ 0.179 0.320 0.457 -0.067 0.064 0.519 0.103 0.078 0.216 0.021 
VEN 0.368 -0.036 -0.178 0.178 0.240 0.027 0.479 0.239 -0.259 0.028 
DCF -0.174 0.275 0.518 -0.037 0.055 -0.199 -0.419 0.072 -0.361 0.250 
TCS 0.321 -0.026 -0.146 0.158 0.309 -0.403 -0.494 0.344 0.277 -0.028 
TCB 0.094 0.216 -0.442 -0.230 0.422 0.302 -0.295 -0.428 0.089 0.259 
SMZ 0.262 0.440 0.073 -0.042 -0.120 -0.015 0.103 0.281 0.467 0.104 
TRI 0.069 0.274 0.160 0.576 0.429 -0.053 0.080 -0.219 -0.181 -0.337 
FLX -0.066 0.413 -0.099 -0.264 -0.024 -0.607 0.378 -0.135 0.002 0.148 
GFB 0.180 0.009 -0.042 0.598 -0.493 -0.034 -0.105 -0.343 0.114 0.372 
ATOR 0.256 0.318 -0.270 -0.055 -0.436 0.060 -0.176 0.021 -0.159 -0.390 
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Table A5.6. Principal component scores by date for the Waterloo WWTP, 2011 – 2015. 
Sample Score 1 Score 2 Score 3 Score 4 Score 5 Score 6 Score 7 Score 8 Score 9 Score 10 
2011May 2.17 1.06 -1.22 1.99 2.09 -0.313 -0.664 0.487 0.726 0.142 
2011November 6.87 -0.29 -0.979 -2.02 -1.22 -0.283 -0.31 -0.346 -0.0735 -0.42 
2012July 1.21 -2.06 -0.458 0.431 1.45 0.564 1.86 -0.571 -0.414 0.849 
2013December 2.13 -2.02 1.1 1.07 0.588 -0.966 -1.24 0.638 -0.952 0.205 
2014March -0.258 -2.33 1.42 -0.213 -0.278 -0.0435 -0.925 -0.137 0.358 -0.436 
2014May 0.707 -0.676 -1.66 0.736 -0.0469 -0.936 0.882 1.1 0.871 -0.0594 
2014July -1.49 -1.19 -0.867 0.217 -0.398 0.82 -0.317 0.345 -0.588 -0.155 
2014August -1.12 -1.48 -0.229 -0.342 -0.348 -0.122 0.561 -0.12 -0.454 0.0225 
2014September -1.54 -2.48 -0.3 -0.701 -0.171 0.126 0.505 -0.281 0.586 0.0877 
2014October -1.73 -1.87 0.121 -0.258 0.0881 -0.393 0.61 -0.841 0.544 -0.914 
2014November -1.06 1.2 -2.56 -0.758 1.4 1.66 -1.31 -1.02 -0.122 -0.0378 
2014December -1.32 2.38 0.413 1.08 0.846 -1.35 0.588 -0.545 -0.857 -0.87 
2015January -0.465 1.43 1.85 0.02 0.68 0.145 -0.433 -0.513 0.87 -0.0978 
2015March -2.21 -0.0788 0.305 -0.571 -0.224 -0.107 -0.71 0.624 0.276 0.0395 
2015Apr11 -1.59 -0.171 0.747 -0.428 -0.249 -0.123 -0.565 0.69 0.251 0.444 
2015May -0.305 1.12 1.36 -1.42 0.382 -1.23 -0.247 -1.07 -0.235 1.05 
2015June -1.2 3.27 -1.47 -1.36 -0.98 -1.05 0.562 0.476 0.141 0.245 
2015Ju1y -0.00269 1.03 0.162 0.105 0.0485 0.524 0.412 0.343 -0.855 -0.584 
2015August -1.57 0.241 -0.238 -0.324 -0.86 0.791 -0.0812 1.23 -0.543 0.218 
20155eptember 2.33 2.05 2.68 -0.238 0.269 1.83 1.01 0.623 0.308 -0.111 
2015November 0.434 0.867 -0.176 2.98 -3.07 0.451 -0.179 -1.12 0.163 0.385 
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A6: Flow Data for the Kitchener and Waterloo WWTPs 
 
This study reported the concentrations of select CECs in wastewater effluents. To allow for 
conversion to load, flow rates for the Kitchener and Waterloo WWTPs over time are provided 
below. Data has been supplied under agreement with the Regional Municipality of Waterloo. 
 
Table A6.1. Average monthly flow at the Kitchener WWTP, 2010 – 2014 reported as 1000 m3/d. 
Data provided by the Region of Waterloo. 
Month 2010 2011 2012 2013 2014 
Jan 62.33571 61.36439 70.461 71.417 70.58483 
Feb 59.77989 63.15564 69.194 67.095 64.65795 
Mar 69.97555 83.21655 72.681 79.369 71.57371 
Apr 69.43803 83.37637 64.744 90.149 94.71034 
May 65.7219 87.33552 64.303 72.424 84.92745 
Jun 67.50947 71.6509 65.54 74.571 73.04732 
Jul 64.72787 62.7379 60.658 70.025 70.13452 
Aug 61.03403 61.73148 59.194 66.158 70.40039 
Sep 62.2614 60.36391 62.148 64.935 78.18814 
Oct 62.924 66.78358 67.659 71.623 72.28735 
Nov 62.563 66.43421 64.654 73.558 75.41153 
Dec 63.379 76.4606 66.942 67.79 71.55768 
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Table A6.2. Average monthly flow at the Waterloo WWTP, 2010 – 2014 reported as 1000 m3/d. 
Data provided by the Region of Waterloo. 
Month 2010 2011 2012 2013 2014 
Jan 42.26545 40.77855 44.595 50.00926 47.356 
Feb 40.01164 41.5695 40.293 45.1985 43.408 
Mar 47.97874 56.94481 42.21 53.31981 51.81 
Apr 44.69987 57.196 39.059 69.45137 61.95 
May 41.11919 56.50074 38.443 57.86919 45.469 
Jun 43.563 45.96687 46.632 41.70617 46.441 
Jul 40.51148 38.05665 35.551 42.74698 48.528 
Aug 36.99581 36.97284 37.377 46.92991 40.838 
Sep 41.16117 40.03507 39.775 49.94497 45 
Oct 43.02774 44.31113 52.006 47.95755 52.676 
Nov 42.691 41.3807 39.774 45.7445 52.791 
Dec 39.992 46.46223 47.96 41.58629 46.457 
 
